Usage of metformin in patients with type 2 diabetes mellitus by Huang, W
  
 
 
 
Usage of metformin in patients with type 2 
diabetes mellitus  
 
 
Weiyi Huang 
BPharm, Guangdong Pharmaceutical University, China 
MPharmSci, University of Tasmania, Australia 
 
 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy (Pharmacy) 
University of Tasmania  
2016
i 
Declaration of Originality 
This thesis contains no material which has been accepted for a degree or diploma by the 
University or any other institution, except by way of background information and duly 
acknowledged in the thesis, and to the best of my knowledge and belief no material previously 
published or written by another person except where due acknowledgement is made in the text 
of the thesis, nor does the thesis contain any material that infringes copyright. 
Weiyi Huang 
15th May 2016 
ii 
Authority of Access 
This thesis is not to be made available for loan or copying for two years following the date this 
statement was signed. Following that time the thesis may be made available for loan and limited 
copying and communication in accordance with the Copyright Act 1968.  
Weiyi Huang 
15th May 2016 
iii 
 
Statement of Ethical Conduct 
The research associated with this thesis abides by the international and Australian codes on 
human and animal experimentation. This research received approval from the Tasmania Health 
and Medical Human Research Ethics Committee (approval reference numbers: H0012876, 
H0014090). 
 
Weiyi Huang 
15th May 2016 
 
  
iv 
 
Statement regarding published work contained in thesis 
The publishers of the articles comprising Chapters 2 to 4 hold the copyright for that content, 
and access to the material should be sought from the respective journals. The remaining non-
published content of the thesis may be made available for loan and limited copying and 
communication in accordance with the Copyright Act 1968. 
 
  
v 
 
Statement of Co-authorship 
The following people and institutions contributed to the publication of work undertaken as part 
of this thesis: 
Candidate: Weiyi Huang (WH)1 
Other authors: Gregory M. Peterson (GMP)1,2 
 Ronald L. Castelino (RLC)1,3 
 Syed Tabish R. Zaidi (STRZ)1 
 
1Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Hobart, Australia  
2Health Services Innovation Tasmania, School of Medicine, Faculty of Health, University of 
Tasmania, Hobart, Australia 
3Sydney Nursing School, University of Sydney, Sydney, Australia 
 
Author details and their roles: 
 
Paper 1, Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to? 
Internal Medicine Journal. 2014;44(3):266-272. 
Located in Chapter 2 
Candidate was the primary author and with GMP and RLC contributed to the idea, its 
development and review of content. GMP and RLC helped to evaluate and edit the manuscript. 
 
Paper 2 Metformin utilisation in Australian community and aged care settings. 
Diabetes Research and Clinical Practice. 2015;108(2):336-341. 
vi 
 
Located in Chapter 3 
Candidate was the primary author and with GMP and RLC contributed to the idea, its 
development and review of content. GMP and RLC helped to evaluate and edit the manuscript. 
STRZ helped to evaluate the statistical analysis and edit the manuscript.  
 
Paper 3 Adverse event notifications implicating metformin with lactic acidosis in Australia. 
Journal of Diabetes and its Complications. 2015;29(8):1261-1265. 
Located in Chapter 4 
Candidate was the primary author and with GMP and RLC contributed to the idea, its 
development and review of content. GMP and RLC helped to evaluate and edit the manuscript. 
 
Paper 4 Lactic acidosis and the relationship with metformin usage: case reports [accepted 
in Medicine®] 
Located in Chapter 5 
Candidate was the primary author and with GMP and RLC contributed to the idea, its 
development and review of content. GMP and RLC helped to evaluate and edit the manuscript. 
 
Paper 5 Lactate levels in chronic metformin users: a narrative review [submitted] 
Located in Chapter 6 
Candidate was the primary author and with GMP and RLC contributed to its development and 
review of content. GMP and RLC helped to evaluate and edit the manuscript. 
 
vii 
 
Paper 6 Metformin: an old drug with clinical value and safety in old patients. Australian 
Pharmacist. 2016; July: 36-38. 
GMP was the primary author and with WH and RLC helped to edit the manuscript. 
 
 
We the undersigned agree with the above stated “proportion of work undertaken” for each of 
the above published (or submitted) peer-reviewed manuscripts contributing to this thesis: 
 
 
  Date:            10/05/2016____________                   10/05/2016_____________   
viii 
 
Acknowledgements 
There are many people without whom which this thesis might not have been written and to 
whom I am greatly indebted.  
I would like to express my sincere gratitude to Professor Gregory Peterson who gave me the 
opportunity to pursue my PhD degree and provided the leadership through my candidature. 
Your phenomenal guidance and tireless efforts have made this project a reality.   
Thank you to Dr. Ronald Castelino for your constant encouragement and keen eye for detail. 
You have been a mentor and friend from the beginning of my PhD journey and I am so grateful 
for your support and friendship.  
I would like to thank all the staff in University of Tasmania Pharmacy, my officemates and my 
friends. Your friendship was valuable to me throughout these past few years.  
I am grateful to my parents who always believe in me and support me without condition. Thank 
you for giving me the freedom to choose this direction even though it led me far away from 
home for such a long time. I hope that I can make you proud.  
 
 
 
 
 
 
 
  
ix 
 
Abstract 
Metformin is an old drug which is widely prescribed for the treatment of type 2 diabetes 
mellitus (T2DM). It is recommended as the first line oral anti-hyperglycaemic agent in 
Australia, United States and most European countries. It reduces haemoglobin A1c (HbA1c) 
by 10-20 mmol/mol (approximately 1-2%), and does not cause weight gain or hypoglycaemia. 
Metformin is well tolerated in most patients and has potential clinical advantages in patients 
with cardiovascular disease. The clinical conundrum facing practitioners while prescribing 
metformin is the potential risk of lactic acidosis, which although rare is often fatal. The current 
official product information recommends that metformin should be avoided or the dosages 
adjusted in patients with coexisting conditions that are likely to increase the risk of lactic 
acidosis. The safe use of metformin is still under debate, which may confuse practitioners when 
prescribing. Thus we aimed to provide more evidence regarding the current prescribing pattern 
and usage of metformin in Australia, and to explore the safety of metformin, especially its 
association with lactic acidosis. 
To achieve this aim, a number of complementary studies were conducted. We evaluated 
the prescribing pattern of metformin in patients who were admitted to a local hospital. The 
main finding of this study was that metformin was often being prescribed ‘inappropriately’ 
with regards to the restrictions listed in the official product information, in terms of usage with 
contraindications and in higher than recommended dosages. Similar results were observed 
when we reviewed the use of metformin in patients who lived in the community or aged care 
facilities receiving either Home Medicines Reviews or Residential Medication Management 
Reviews respectively. This study included more than 6,000 patients living across Australia. 
Our findings were consistent with those conducted in other countries.  
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To evaluate the potential association between the use of metformin and lactic acidosis, 
we reviewed all the potential adverse drug reaction cases of metformin which were reported to 
the Therapeutic Goods Administration (TGA) of Australia from 1971 October 2014. A total of 
152 potential cases of lactic acidosis associated with metformin were reported to the TGA. 
Approximately 75% of these cases had at least one clinical condition which itself might cause 
acidosis. The incidence of metformin-associated lactic acidosis (MALA) was estimated to be 
2.3 (95%CI, 1.5-3.1) cases per 100,000 patient-years between 1997 and 2011. This relatively 
low incidence of MALA may be explained by the nature of spontaneous reports to the TGA. 
In addition, we reviewed the cases of patients who were admitted to a local hospital with lactic 
acidosis. Over a four-year period, 139 patients were identified using the digital medical record; 
only 23 patients had T2DM and 11 patients had been taking metformin.  
To further verify the low incidence of lactic acidosis in metformin users, we conducted 
a literature review on regular tested lactate level among metformin users. Limited studies have 
reported the lactate levels with continued metformin usage. Few studies reported that the lactate 
level in metformin users did not alter after the initiation of metformin. However, compared to 
the lactate level of patients without being treated with metformin, the level in metformin-
treated patients was, on average, higher; but, remained within the normal range.   
The findings of studies contained in this thesis indicate that it is generally safe to use 
metformin in most patients with T2DM. Recently, therapeutic guidelines in Australia have 
modified the prescribing recommendations for metformin, with less restrictions in patients with 
so-called “contraindications”. It is necessary to update the official product information for 
metformin, which will give a clearer recommendation to prescribers in practice.  
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Thesis overview 
Metformin is widely used in the treatment of type 2 diabetes mellitus (T2DM). The major 
barrier for practitioners to prescribe metformin is the concern of developing lactic acidosis 
(LA). The caution may be related to the other biguanide, phenformin, which was used to treat 
T2DM; this drug was removed from the market due to the association with high incidence of 
LA. The concerns of LA in metformin-treated patients are under debate, as in comparison to 
phenformin, the reported incidence of LA in metformin users is much lower.  
Limited studies have been conducted in Australia regarding the use of metformin. This 
thesis, which explores the current usage of metformin in Australia and the LA cases associated 
with metformin, is divided into five parts. 
Part A of this thesis (Chapter 1) includes the background information on: (i) the current 
facts of T2DM in Australia; (ii) metformin and its clinical usage; and (iii) LA and its potential 
association with metformin. Diabetes is one of the most common chronic diseases in Australia, 
with T2DM accounting for approximately 85% of diabetes cases. Chronic kidney disease 
(CKD) is both a complication and an independent comorbidity of diabetes, which has been 
estimated to affect approximately 50% of patients with T2DM globally. There are limited 
medication choices to treat T2DM in patients with CKD effectively; as most of the newer drugs 
have not been studied in this population. Metformin has been used for more than half a century, 
provides the best effect in reducing haemoglobin A1c (HbA1c) among all the oral anti-diabetic 
medications and has evidence in decreasing the risk of diabetic related complications. 
However, its potential benefits in macro-and microvascular effects may be overlooked due to 
the concern of LA. The official product information presents a list of contraindications to the 
use of metformin, including: (i) acute or chronic diseases which may cause tissue hypoxia (i.e. 
cardiac failure); and (ii) conditions with the potential to alter renal function (i.e. dehydration), 
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as well as renal dysfunction (creatinine clearance < 60 ml/min). Studies have reported that the 
incidence of LA in metformin-treated patients is low. According to a Cochrane review, the 
estimated LA incidence among the patients treated with antidiabetic medications was 
approximately 4.3 per 100,000 patient-years among metformin users and 5.4 cases in non-
metformin users.   
Given this background, we aimed to undertake two medication review studies, which 
explored the prescribing patterns of metformin in patients with T2DM who were admitted to 
the hospital and those who were living in the community or aged care facilities in Australia 
(Part B, Chapter 2 & 0). The primary objective was to explore the prescribing pattern of 
metformin in practice, in terms of the use of the drug in the presence of contraindications and/or 
in excessive dosage based on renal function. The first study (Chapter 2) reviewed a total of 301 
patients receiving metformin who were admitted to a local hospital over an 8-month period in 
2012. At admission, more than 30% of patients receiving metformin were found to have 
contraindications to metformin, and more than 20% of patients were prescribed with excessive 
dosage according to their renal function. The most common contraindications in this study were 
cardiac failure and liver dysfunction. Four patients were found to have potential LA (defined 
as lactate > 5.0mmol/L and pH < 7.35); however, all these patients had contraindications to 
metformin use. The other medication review study (0) pertaining to more than 6,000 patients 
in Australia revealed that approximately 12% of patients living in the community and 17% of 
patients living in aged care facilities were receiving metformin inappropriately.  
Although we found that metformin was often being used in patients with 
contraindications to its use or in excessive dosage in decreased renal function, it seems 
generally safe to use this anti-diabetic medication. Part C of this research (Chapter 4 & Chapter 
5) evaluated the LA cases reported in metformin-treated patients in Australia. A total of 152 
LA cases, which were suspected to have association with the use of metformin, were reported 
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to the Australian Therapeutic Goods Administration from January 1971 to October 2014 
(Chapter 4). More than 25% of patients were reported to have pre-existing contraindications to 
the use of metformin and approximately 75% had underlying clinical conditions which may 
have caused acidosis. The incidence of metformin-associated LA (MALA) was estimated to be 
2.3 cases per 100,000 patient-years. The study in Chapter 5 was conducted with an intention to 
collect more detailed medical information on LA in patients receiving metformin who were 
admitted to the local hospital. Between 2010 and 2013, of the 139 patients admitted with LA, 
only 23 patients had T2DM and 11 patients had been prescribed with metformin. Based on the 
findings from two studies in Part C, the incidence of LA in metformin-treated patients in 
Australia was low and the risk of developing LA may be overemphasised in patients treated 
with this agent. 
To further verify the findings in Part C, a literature review was performed to evaluate 
the measurement of lactate levels in chronic metformin users (Part D, Chapter 6). Limited 
research has been conducted to monitor the lactate levels in patients treated with metformin. 
The lactate levels were mostly documented in the case reports of MALA (under acute 
conditions). Most of the studies included in this review reported that the lactate levels were 
higher in chronic metformin-treated patients compared to those of non-metformin users, or the 
levels at baseline (before initiating metformin therapy). However, the lactate levels in 
metformin users have mostly been reported remaining in the normal range, even in those 
studies including patients with other underlying clinical conditions.   
Part E (Chapter 7) of this thesis presents a general discussion and conclusion of the 
research. 
 
 
 
 
 
 
Part A  
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Chapter 1 Background  
 Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is one of the most prevalent and fastest growing chronic 
diseases globally and in Australia.1 T2DM is one of the three main types diabetes mellitus 
(DM), which also includes type 1 diabetes mellitus (T1DM) and gestational diabetes. DM 
includes a group of metabolic disorders characterised by hyperglycaemia and abnormalities in 
carbohydrate, fat and protein metabolism. It is a source of a range of metabolic disturbances 
which result from inadequate insulin secretion, resistance to the actions of insulin or both. 
T2DM accounts for approximately 85% of DM cases in Australia, and is usually characterised 
by the presence of both insulin resistance and relative insulin deficiency.2  
 
 Epidemiology 
Diabetes currently affects over 415 million adults, and in addition, there are 318 million adults 
with impaired glucose tolerance.3 It is currently estimated that 1.7 million Australians are living 
with diabetes and it is thought that half a million of these people are living with undiagnosed 
T2DM. Furthermore, it is estimated that approximately 280 Australians develop diabetes every 
day.4  Most of the growth in diabetes is due to T2DM, which can be a result of the aging of the 
population, a reduction in physical activity, the obesity epidemic and decreased mortality in 
those with diabetes.5 Overall, T2DM is much more common in males as compared to females.5 
Of the 787,500 people reported as having T2DM in 2007-08, 56% of them were males and 
44% were females.6 Approximately 92% of T2DM patients were 45 years old or more and 45% 
were 65 years or older.6 
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 Burden of disease 
According to the latest available data from Australian Institute of Health and Welfare (AIHW), 
T2DM accounted for a least 60% of DM expenditure in 2009-09. Almost $1,507 million was 
spent on DM, which increased by 86% between 2000-01 and 2008-09 while for all disease 
increased by 60% in the same period. It is estimated that the total cost of diabetes is $14.6 
billion each year in Australia.7 Using a conservative estimate, diabetes was projected to be the 
sixth leading cause of burden of disease and injury in Australia in 2010 (contribution of 
diabetes to coronary heart disease (CHD) and stroke not included), and responsible for nearly 
6.6% of the total disease burden.8 T2DM was estimated to account for the great majority (94%) 
of diabetes burden in 2010, and the ranking of T2DM as a cause of disease burden is projected 
to increase over time.8      
 
 Complications of diabetes mellitus 
Complications associated with T2DM can arise early in the course of the disease or develop 
over a number of years. Long-term complications ofT2DM include disease of the large blood 
vessels (macrovascular disease) that can lead to conditions such as CHD, stroke and peripheral 
vascular disease; and disease of the small blood vessels (microvascular disease) that can cause 
chronic kidney disease (CKD), nerve damage and retinopathy.9 T2DM is the most common 
cause of severe kidney disease in Australia.5  
CKD is both a complication of diabetes, and an independent comorbidity presented 
before diabetes onset. CKD, defined as an estimated glomerular filtration rate (eGFR) of less 
than 60 ml/min per 1.73m2, is a long-term health condition where a person has kidney damage 
and/or reduced kidney function lasting for 3 months or more.10 In addition, both diabetes and 
CKD are known to be under-reported in the Australian and the global mortality statistics, often 
being omitted from death certificates as contributory causes of death.11, 12 Based on AusDiab 
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data, more than 90% of the adult diabetes population in Australia with evidence of kidney 
damage exhibited albuminuria, either alone or in combination with a low estimated eGFR.13  
Recently, a review regarding the epidemiology of T2DM and associated CKD 
suggested that CKD was estimated to affect about 50% patients with T2DM globally, and the 
presence of CKD and its severity markedly influenced disease prognosis.14 In patients with 
T2DM, CKD was found to be associated with excess mortality.15, 16 T2DM is the single leading 
cause of ESKD globally, accounting for approximately one-third of all patients initiating renal 
replacement therapy.17 As of 2012, the prevalence of DM-ESKD in Australia was 208 per 
million population.13 Together with the population with glomerulonephritis and hypertensive 
renal disease, the estimated annual incidence of treated DM-ESKD among Australian aged 25 
years and older was approximately 1 case per thousand.13 
 
 Mortality  
Globally, approximately 1.5 million deaths were directly caused by DM in 2012.18 In Australia, 
a total of 15,095 deaths in 2012 were due to some degree of DM (1 in 10 of all deaths).19 DM 
itself is not often the reason directly leading to death, but one of its complications that with be 
listed as the underlying cause of death.20 The diabetes-related deaths were reported to be 30.9 
persons per 100,000 people in 2010 (Figure 1). In Australia, when DM was reported as any 
cause of death (underlying or associated), the most common contributing causes of death were 
coronary heart disease (47%), hypertensive diseases (30%), heart failure (21%), kidney failure 
(21%), and cerebrovascular disease (20%).13 T2DM was listed as an underlying or associated 
cases of death in approximately 50% of all the cases of DM. Males were more likely to die 
from DM as any cause of death than females, with age-standardised death rates of 78 and 50 
per 100,000 population, respectively.20 
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Figure 1 Death rates for diabetes as the underlying cause of death in Australia, 1997-201021  
 
 Drug treatment for T2DM 
The aim of the treatment in DM is to achieve normal or near normal blood glucose levels, to 
ameliorate the symptoms of hyperglycaemia, to reduce the risk of microvascular and 
macrovascular complications, and to reduce mortality and improve the quality of life. In 
T2DM, this may be achieved by lifestyle modification (i.e. diet and exercise), oral medications 
and insulin injections; in T1DM the ‘missing insulin’ has to be replaced, resulting in life-long 
insulin injections.  
Early initiation of pharmacologic therapy is associated with improved glycaemic 
control and reduced long-term complications in T2DM. Drug classes used for the treatment of 
T2DM include in  
Table 1, which is summarised based on the recommendations/statements of Australian 
Medicines Handbook (AMH, 2016), General practice management of type 2 diabetes 2014-15 
(Diabetes Australia), Anti-diabetic agents for use in type 2 diabetes 2016 (Canadian Diabetes 
Association) and the primary literature. 
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Table 1 Drugs for T2DM 
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Class/drug Expected decrease 
in HbA1c 
(mmol/mol) 
Effect on 
weight 
Hypoglycaemia  Comments  
Oral  
Metformin 10-20 Nil (or 
decrease) 
Negligible risk as monotherapy.   Improved cardiovascular outcomes n 
overweight subjects; 
 GI adverse effects are common; 
 Lactic acidosis is very rare.  
Sulfonylureas 
(glibenclamide, gliclazide, 
glimepiride, glipizide) 
10-20 Increase Glibenclamide and glimepiride may 
cause rates of hypoglycaemia.  
 All insulin secretagogues reduce 
glycaemia similarly. 
Dipeptidyl peptidase-4 
inhibitors  
(alogliptin, linagliptin, 
saxagliptin, sitagliptin, 
vildagliptin) 
5-10 Nil Negligible risk as monotherapy.  Improved post-prandial control; 
 Caution with Saxagliptin in heart 
failure; 
 Rare cases of pancreatitis; 
 Long-term safety and efficacy data are 
limited. 
Thiazolidinediones  
(pioglitazone, rosiglitazone) 
5-15 Increase Negligible risk as monotherapy.  Between 6 and 12 weeks required to 
achieve full glycaemic effect; 
 Ineffective in up to 30% of patients; 
 Adverse effects include cardiovascular 
controversy (rosiglitazone), increased 
LDL-C (rosiglitazone); 
 Rare risk of bladder cancer with 
pioglitazone. 
Acarbose 5-10 Nil Negligible risk as monotherapy.  Reduces postprandial hyperglycaemia 
 Associated with GI side effects; 
 Not recommended as initial therapy in 
people with marked hyperglycaemia 
(HbA1c>8.5%). 
Sodium-glucose co-
transporter 2 inhibitors 
(canagliflozin, dapagliglozin, 
empagliflozin) 
5-10 Decrease  Low risk with monotherapy 
(increased risk in combination with a 
sulfonylurea or insulin); 
 
 Rely on adequate renal function; 
 Increase urinary glucose, adverse 
effects include vaginal candidiasis and 
urinary tract infection; 
 Long-term safety and efficacy data are 
lacking. 
Parenteral  
11 
 
Insulin 15-40 Increase Significant risk.   Greater risk of hypoglycaemia and 
weight gain than sulfonylureas. 
Glucagon-like peptide 1 
analogues  
(exenatide, liraglutide) 
5-15 Decrease Negligible risk as monotherapy.  Improved post-prandial control; 
 GI side effects are common; 
 Rare cases of pancreatitis; 
 Long-term safety and efficacy data are 
limited. 
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An increasing range of medications for the treatment of T2DM are now available, and 
each medication has its own efficacy in the treatment of T2DM (Table 1). Sulfonylureas, 
thiazolidinediones (TZDs), and insulin are more likely to be associated with weight gain when 
compared to the other anti-diabetic medications.22-24 Dipeptidyl peptidase-4 (DPP-4) inhibitors 
showed less potency in reduction of HbA1c than metformin or sulfonylureas.25 Sulfonylureas 
are associated with a high risk of severe hypoglycaemia as monotherapy and in combination 
with metformin (compared to metformin plus a DPP-4 inhibitor or a sodium-glucose co-
transporter 2 (SGLT-2) inhibitor).25, 26 SGLT-2 inhibitors increased the risk of genital mycotic 
infections compared to all other monotherapies and metformin-based combinations.27 Both 
metformin and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a higher 
risk of gastrointestinal adverse effects.25  
Metformin is effective in correcting hyperglycaemia and has a long history of use, 
demonstrated safety and tolerability. Besides, metformin is associated with lower 
cardiovascular mortality compared to sulfonylureas.28-30 In addition, two ongoing randomized, 
double-blind clinical trials [Metformin in CABG trial, MetCAB (NCT01438723) and 
Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation 
Myocardial Infarction Trial, GIPS-III (NCT01217307)31 will help to elucidate whether 
metformin can reduce infarct size and improve left ventricular function after ischaemia-
reperfusion injury.32 Metformin treatment produced more weight loss in patients with T2DM 
versus TZDs or sulfonylureas monotherapy.27 Metformin also costs less in comparison to most 
of the other anti-diabetic medications (sulfonylureas and TZDs are also relatively low cost).33 
Metformin is the medication of choice and recommended to all patients with T2DM 
unless contraindicated and not tolerated.9 Second- and third-line agents may be necessary in 
addition to metformin when T2DM is poorly controlled. When additional agent(s) are required, 
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an individualised approach is recommended based on patient needs (i.e. efficacy, risk of 
hypoglycaemia, major side effects, weight gain and costs); the agent should work in a different 
way and be chosen to work synergistically.9  
Achieving glycaemic control has been shown to both prevent and delay the progression 
of CKD.24, 34, 35 Intensive diabetes management with the goal of achieving near 
normoglycaemia has been shown to delay the onset of microalbuminuria and the progression 
of microalbuminuria to macroalbuminuria in patients with T2DM in a large prospective 
randomised study.9 Besides, it is important to note that CKD can influence the 
pharmacokinetics of most of the anti-diabetic medication (except gliclazide, glipizide, 
pioglitazone, rosiglitazone and linagliptin), which potentially presents as enhanced risk of 
hypoglycaemia, drug-to-drug interactions and/or side effects.36 Therefore, the daily dosage of 
each anti-diabetic medication should be reduced according to the renal impairment. In 
Australia, the dosage recommendation is based on patients’ creatinine clearance (CrCl) (Table 
2). The Australian Medicines Handbook (AMH) classifies reduction in the kidney function 
based on the estimation of CrCl into three categories; mild (25-50 ml/min), moderate (10-25 
ml/min) and severe (< 10 ml/min). CrCl is used to guide the medication dosage adjustment in 
patients with renal impairment.  
 
Table 2 Anti-diabetic medications dosing recommendations in renal impairment 
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    AMH 2016 Product information 
Medications Maximum daily 
dosage with 
normal renal 
function 
Renal impairment, dosage 
recommendation (if any) 
Contraindicated in 
renal function of    
Renal impairment, dosage 
recommendation (if any) 
Contraindicated in 
renal function of    
Metformin  3000mg CrCl 60-90 ml/min, 2000 
mg/day; 
CrCl 30-60 ml/min, 1000 
mg/day; 
CrCl 15-30 ml/min, 500 
mg/day. 
CrCl < 15 ml/min  N/A CrCl < 60 ml/min 
Glibenclamide  20 mg * Gliclazide or glipizide 
preferred.  
  N/A Severe renal 
impairment 
Gliclazide  320mg ***   
Glimepiride  4mg * N/A CrCl < 30ml/min 
Glipizide  40mg ***   
Pioglitazone  45mg ***   ***   
Rosiglitazone  8mg ****   
Alogliptin 25mg CrCl 30-50 ml/min, 
12.5mg/day;  
CrCl < 30 ml/min, 6.25 
mg/day. 
  CrCl 30-50 ml/min, 12.5mg/day;  
CrCl < 30 ml/min, 6.25 mg/day. 
  
Linagliptin 5mg ***   ***   
Saxagliptin  5mg CrCl < 50 ml/min, 
2.5mg/day. 
  N/A CrCl < 60 ml/min 
Sitagliptin  100mg CrCl 30-50 ml/min, 50 
mg/day; 
CrCl < 30 ml/min, 25 
mg/day. 
  CrCl 30-50 ml/min, 50 mg/day; 
CrCl < 30 ml/min, 25 mg/day. 
  
Vildagliptin  100mg CrCl < 60 ml/min, 50 
mg/day. 
  eGFR < 60 ml/min, 50mg/day.   
Exenatide  20µg CrCl 30-50 ml/min, 
possible increased risk of 
adverse effects.  
CrCl < 30 ml/min CrCl > 30 ml/min*** CrCl < 30 ml/min 
Liraglutide  1.8mg ****   CrCl < 30 ml/min****   
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Canagliflozin  300mg CrCl 45-60 ml/min, 100 
mg/day. 
  
                             
CrCl < 45 ml/min CrCl >60 ml/min or eGFR >60 
ml/min/1.73m2: ***; CrCl 45-60 ml/min 
or eGFR 45-60 ml/min/1.73m2: 
100mg/day. 
CrCl < 45 ml/min or 
eGFR <45 
ml/min/1.73m2 
Dapagliflozin  10mg N/A CrCl < 60 ml/min CrCl >60 ml/min or eGFR >60 
ml/min/1.73m2 *** 
CrCl <60 ml/min or 
eGFR <60 
ml/min/1.73m2 
Empagliflozin  25mg N/A CrCl < 45 ml/min eGFR >45 ml/min/1.73m2 *** eGFR <45 
ml/min/1.73m2 
Acarbose  150mg N/A CrCl < 25 ml/min N/A CrCl < 25 ml/min 
Insulins    **   **   
The dosage recommendation is not including for (i) initiation of the drug; (ii) children; (iii) controlled release product; (iv) in combination with other anti-
diabetic medications. Some of the drug should be given in divided dosage instead of one dose with the maximum dosage.  
* Avoid glibenclamide/glimepiride in renal impairment due to the increased risk of hypoglycaemia; 
** May require dosage reduction; 
*** No dosage adjustment required; 
**** Limited data in patients with renal impairment. 
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 Metformin  
Metformin, which belongs to the class of biguanides, has been used widely in the treatment of 
T2DM. It has been found to be safe and efficacious both as monotherapy and in combination 
with other oral anti-diabetic medications and insulin. It offers the therapeutic effect of 
glycaemic control without inducing hypoglycaemia or weight gain.37 Besides, the drug has 
shown advantages of counteracting the cardiovascular complications associated with diabetes 
and producing a reduction in the risk of diabetes-related morbidity and mortality.37-39 It is 
recommended as the first choice for patients with diagnosed of T2DM in Australia,9 European 
countries, United Kingdom (UK) and United States (US).40 But lactic acidosis (LA), as a rare 
adverse effect associated with metformin, is the major barrier for practitioners to prescribe this 
drug.  
 
 Mechanism of action 
Metformin does not stimulate insulin release but does require the presence of insulin to exert 
its antihyperglycaemic effect.41 It mainly reduces hepatic glucose production and increases 
peripheral utilisation of glucose.42 The exact mechanism of action of metformin remains 
obscure. There are several possible biological activities have been suggested in both human 
and animal studies, which include reducing gluconeogenesis, increasing glucose uptake and 
utilisation in skeletal muscle, and delaying of intestinal glucose absorption.  
 
 Metformin’s effect on liver 
Metformin’s overall antihyperglycaemic effect is to reduce the rate of hepatic gluconeogenesis 
in patients with T2DM, thereby, decreasing endogenous glucose production, and lowering both 
fasting and postprandial plasma glucose.43-47 In clinical studies, metformin treatment lowered 
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the glucose production by 25% to 30%.43, 47 Another study showed that metformin therapy 
decreased endogenous glucose production by a mean of 19%, while the fasting and 
postprandial plasma glucose concentrations decreased by 20% and 25%, respectively.42 Animal 
studies showed similar results in reducing gluconeogenesis as those found in clinical studies. 
Several mechanisms have been proposed to explain the inhibitory action on hepatic 
gluconeogenesis, including changes in enzyme activities48-50 or a reduction in hepatic uptake 
of gluconeogenic substrates.51     
Several possible mechanisms in inhibiting hepatic gluconeogenesis by metformin in the 
intracellular environment have been proposed. Metformin inhibits the respiratory chain 
complex I in the mitochondria (Figure 2), which results in reducing adenosine triphosphate 
(ATP) levels and increasing adenosine monophosphate (AMP). Gluconeogenesis is reduced as 
decreased ATP levels limit glucose synthesis; besides, decreased ATP and increased AMP 
levels lead to reduced activity of pyruvate carboxylase and fructose-1, 6-biphosphatase, which 
are required in gluconeogenesis.52, 53 It was reported recently that metformin inhibited the redox 
shuttle enzyme, mitochondrial glycerophosphate dehydrogenase (mGPD), resulting in an 
increased cytosolic redox state. This impairs the conversion of lactate to pyruvate, leading to 
decreased gluconeogenesis and accumulation of lactate,54 52, 55 which is associated with 
increased risk of LA. The inhibition of mGPD also contribute to the effect of decreased ATP 
and increased AMP levels.  
Besides, metformin also decreased gluconeogenesis via an adenosine monophosphate-
activated protein kinase (AMPK) dependent pathway (Figure 2). It has been proposed that the 
liver kinase B1/adenosine monophosphate-activated protein kinase (LKB1/AMPK) pathway 
mediates the action of metformin in hepatic gluconeogenesis. 56, 57  The decreasing ATP and 
increasing AMP level actives the AMPK which suppresses the lipogenesis gene expression in 
the nucleus and acetyl-CoA carboxylase (ACC, lipogenic enzymes) activity, thus leading to 
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decreased lipogenesis.58 A more recent study showed that intra-duodenal infusion of metformin 
activated the duodenal AMPK glucagon-like peptide-1 receptor protein-kinase-A dependent 
signal pathway to lower hepatic glucose production and plasma glucose in rat models of obesity 
and diabetes.59 
Besides, studies have suggested that metformin stimulates glycogenolysis and glycolysis in 
short-term periods, and ameliorates hyperglycaemia and insulin resistance as long-term effects 
via AMPK activation.53, 57, 60, 61 It has been suggested that metformin may act on the AMPK 
cascade and activate the catabolic pathways, such as glycogenolysis and glycolysis.62 Also, a 
study suggested that the reduction of glycogenolysis in T2DM was associated with decreased 
cycling of glucose 6-phosphatase (G6Pase), which was required for the production of a 
phosphate group and glucose; therefore, it reduced the glucose production. It was reported that 
metformin could increase levels of the active forms of both glycogen synthase and 
phosphorylase, indicating increased glycogen turnover.63 
 
Figure 2 Potential molecular mechanisms of the action of metformin in gluconeogenesis and 
lipogenesis 
Metformin inhibits the respiratory chain complex I in the mitochondria, which results in reducing ATP 
levels and increasing AMP. This lead to reduced activity of pyruvate carboxylase and fructose-1, 6-
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biphosphatase.52, 58 The decreasing ATP and increasing AMP level also actives AMPK, which 
suppresses the lipogenesis gene expression in the nucleus and ACC activity, thus leading to decreased 
lipogenesis.58 Metformin alsoinhibits mGDP, resulting in an increased cytosolic redox state, which 
impairs the conversion of lactate to pyruvate54 and contributes to the result of decreased ATP and 
increased AMP levels. ACC: acetyl-CoA carboxylase; ATP: adenosine triphosphate; AMP: adenosine 
monophosphate; mGPD: mitochondrial glycerophosphate dehydrogenase  
 
 Metformin’s effects on other tissues 
Metformin has been reported to act on other tissues, including skeletal muscle and adipose 
tissue. Several studies have showed that administration of metformin enhances glucose uptake 
and glycogen synthesis in the muscle of diabetic animals64, 65 and patients with T2DM.66 It has 
been suggested that most of insulin-stimulated glucose utilisation happens in skeletal muscle,67, 
68 which may be attributed to the AMPK pathway. Furthermore, studies found that metformin 
affected lipid metabolism and turnover in skeletal muscles, which may be related to the 
suppression effect of metformin on the fatty acid oxidation in oxidative muscles.69 
Although adipose tissue is not a major site of metformin’s action, metformin appears 
to have effects on it. Metformin has been shown to increase lipolysis, which may contribute to 
insulin sensitisation through the decrease of systemic free fatty acid levels; and it has been 
shown inhibition effect on lipogenesis in subcutaneous fat depot, which may contribute to 
reduced fat mass.69, 70 Metformin may also impact on the endocrine function of adipose tissue 
through the modulation of adipokine synthesis or excretion, including leptin, adiponectin and 
visfatin.69 The activation of AMPK by metformin could also affect adipose tissue.  
Besides, adipose tissue dysfunction contributes to the pathophysiology of polycystic 
ovary syndrome (PCOS). The cause of PCOS is not completely understood; while PCOS is 
associated with elevated levels of insulin in the blood. When the blood glucose level does not 
respond to normal level of insulin, the pancreas produces more insulin, which will cause excess 
production of insulin (called hyperinsulinemia). Insulin resistance and hyperinsulinemia can 
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occur in women with PCOS. Metformin is also used to treat PCOS in selected situations. It 
appeared to affect ovarian function through the alleviation of insulin excess acting upon the 
ovary and through direct ovarian effects.71, 72 Long-term metformin treatment may increase 
ovulation, improve menstrual cycles and reduce serum androgen levels in these patients.73 
 
 Pharmacokinetics  
The pharmacokinetic properties of metformin have been investigated in healthy subjects and 
also in patients with T2DM. The mean half-life (t1/2) of metformin in plasma has been reported 
as approximately 5 hours.74  
Metformin is found to be poorly absorbed from the stomach, but the small intestine is 
suggested as the site for most absorption of the drug.75 It has been reported that metformin 
concentration is high in the small intestine76, 77 and decreases the intestinal absorption of 
glucose,78 which leads to lower postprandial blood glucose levels. Studies found that hepatic 
uptake and renal excretion of metformin are mediated by organic cation transporters (OCTs),79 
which are found in the small intestine,79-81 the liver,79, 82 the skeletal muscle79 and the kidney.79, 
83 At therapeutic doses of oral metformin, steady-state plasma concentrations of metformin 
reaches in 24 to 48 hours and are generally less than 1 µg/mL (average steady state 
concentration); even in maximum therapeutic doses (3,000 mg per day), metformin plasma 
levels would not generally exceed 5 µg/mL.84 The blood glucose lowering effect of metformin 
develops over at least 10 days,85, 86 suggesting that metformin has a long residence time in the 
liver or other compartments.74   
Metformin does not bind to plasma proteins, which is due to its low lipophilic molecular 
structure. The actual volume of distribution (Vd) of oral metformin following multi-dosing has 
been reported as approximately 300 L, which indicated that there was considerable tissue 
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uptake of metformin.74 Metformin is slowly taken up into erythrocytes in previous studies.87, 88 
The peak concentrations in plasma would be much higher than in erythrocytes after a single 
dose; with long-term dosing, the concentrations of metformin in erythrocytes would have much 
less fluctuation in erythrocytes than in plasma.87 Besides, the plasma concentration of 
metformin was undetectable 24 hours after a single dose oral administration; while it remained 
detectable in erythrocyte up to 48 hours.87 The relatively stable concentrations in erythrocytes 
should be able to be detected in patients after exposure to metformin over 1 to 3 days.74 There 
was a doubt that the clearance of metformin would have been slowed down due to its 
distribution into erythrocyte. But the clearance of metformin is four to five times more quickly 
comparing to creatinine, it would not be necessary to worry about the accumulation of 
metformin in erythrocyte.89  
Metformin does not undergo metabolism in either healthy humans or diabetic patients.84 
Metformin undergoes rapid renal excretion, which is the major mode of elimination of 
metformin. The kidney function is critical for the elimination of metformin. As a small and low 
lipid soluble molecule, metformin is filtered at the glomerulus and undergoes passive 
resorption; and the uptake of metformin is mediated by cation transporters in the kidney.74 A 
dosage reduction of metformin is required in patients with kidney disease.  
 
  Metformin in clinical use 
Metformin is mainly used in the treatment of T2DM.  It is the most commonly prescribed oral 
anti-diabetic medications, and was also one of the top 10 commonly prescribed medicines in 
Australia in 2014.90 Metformin is also used for other indications, such as PCOS.  
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 Clinical benefits of metformin  
Besides its anti-hyperglycaemic effect, clinical studies have shown the benefits of metformin 
in patients with complications including micro- and macrovascular complications,91 and the 
potential clinical advantages in those with cardiac disease and heart failure.39    
The United Kingdom Prospective Diabetes Study (UKPDS) (a landmark study of the 
effect of different diabetes therapies on vascular complications in people with T2DM) showed 
that metformin (with intensive glucose control) appeared to decrease the risk of diabetes-
related endpoints in overweight patients, and was associated with less weight gain and fewer 
hypoglycaemic attacks compared to insulin and sulphonylureas.37, 92 In addition, metformin 
monotherapy showed significant decreases in any diabetes-related endpoint (sudden death, 
death from hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, 
heart failure, stroke, renal failure, amputation [of at least one digit], vitreous haemorrhage, 
retinopathy requiring photocoagulation, blindness in one eye, or cataract extraction), all-cause 
mortality, and stroke, in comparison to chlorpropamide, glibenclamide, or insulin.37 In their 10 
years post-trial follow-up report, metformin still showed its advantages compared to other 
diabetic medications.92 Studies elsewhere have also reported significant improvement of all-
cause mortality and cardiovascular mortality in metformin-treated patients.93, 94  
Studies have shown that metformin reduces the risk of hospitalisation for 
cardiovascular disease,94 stroke,95 and myocardial infarction.96 An observational study in 
elderly patients with DM and heart failure found that metformin reduced hospital readmission 
and lowered the death rate during the years after initial hospitalisation.97  
Metformin has shown effect on anti-oxidative stress.   These effects of metformin may 
also contribute to the treatment of clinical conditions such as inflammation, neurodegeneration 
(Alzheimer’s disease and Parkinson’s disease) and tumour formation.98 Metformin may also 
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improve the lipid profile,44, 99 by reducing circulating triglycerides and free fatty acids, although 
so far there is no consensus on evidence to confirm these effects.  
 
 Side effects of metformin 
Gastrointestinal side effects are the most common adverse effects with metformin treatment; 
these include nausea, vomiting, diarrhoea, abdominal pain and loss of appetite.84, 100 These 
undesirable effects occur most frequently during the initiation of therapy and generally resolve 
spontaneously after continuous treatment. Malabsorption of vitamin B12 is another common 
side effect has been observed, which was reported to reduce in intestinal absorption of vitamin 
B12 in up to 30% of patients, in patients with long-term metformin therapy.101, 102  
 
 Lactic acidosis and its relation with metformin 
Although metformin is recommended as the first choice in treating T2DM, a common 
conundrum for practitioners in prescribing metformin is that it may cause LA. The concern of 
prescribing metformin may be affected by phenformin, which was another biguanide used to 
treat T2DM. Phenformin, however, was withdrawn from the market due to its high incidence 
of LA and deaths. Metformin was removed from the market in US in 1977 and many other 
countries; Australia recommended severe restrictions on its use. In 1995, metformin was 
reintroduced to the market in the US.103  
Metformin-associated LA (MALA) and metformin-induced LA (MILA) were used to 
describe the LA in metformin users. ‘Metformin-associated’ would mostly refer to situations 
of both elevated metformin concentration and associated pathology of LA; while ‘metformin-
induced’ was used in describing LA cases with high plasma metformin concentrations and no 
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other potentially causative aetiologies.104 It has been reported that LA occurs in patients 
(without other complications) with metformin overdose.105, 106  
At therapeutic dosage, the incidence of LA among patients prescribed metformin is 
thought to be 2-9 cases per 100,000 patient-years, this range was referred to generally as ‘the 
incidence of MALA’. But the reported incidence of LA in metformin users largely varied in 
studies, ranging from 1.5 to 530 per 100,000 patient-years.26, 107-111 A study conducted in a 
tertiary hospital in Queensland (Australia) reported an estimated incidence of 530 per 100,000 
patient-years.107 The selection of patients who were admitted to the hospital mostly resulted a 
higher calculated rate of incidence. A recent pharmacoepidmiological study in Japan reported 
that the crude incidence of LA was 5.95 per 100,000 patient-years, which based on 30 cases of 
LA among 280,000 treated T2DM patients with more than 500,000 patient-years of follow-
up.112 The authors also pointed out metformin was not associated with risk of LA; however, 
patients with T2DM and CKD were seven-fold more likely to develop LA than those without 
CKD.  
A review summarised the mortality of rate of LA in metformin users, which varied 
markedly from literatures (from 3% to 61%), but the rate was more frequently reported at 
33%.113 The challenge to correctly determine the factors with which mortality is associated 
(rather than determining the mortality rate itself). The contribution of metformin in these LA 
cases may be overemphasised: (i) in most of the cases, patients were reported with other clinical 
conditions which could lead to LA; and (ii) the metformin concentration was not usually 
measured. The term “mixed LA in metformin-treated patients” has been used, suggesting that 
“mixed” would better reflect the combination of other factors.113 In addition, there is no 
randomised controlled trial has been conducted to assess the association between metformin 
and LA, and so far, no correlation between metformin and lactate level has been established.  
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 Lactate and lactic acidosis 
The normal level of lactate is about 0.3 - 1.3 mmol/L with a balance between production and 
clearance. The liver removes approximately 70% of lactate.114 In the liver, under normal 
conditions, more than half of lactate in the body is converted to glucose (gluconeogenesis) and 
half is further metabolised to CO2 and water in the citric acid cycle. Other tissues can use lactate 
as a substrate and oxidise it to CO2 and water, and mitochondria-rich tissues (such as skeletal 
and cardiac myocytes, proximal tubule cells) remove lactate by converting it to pyruvate. The 
kidney is also responsible for the removal of lactate, which undergoes renal uptake and 
metabolism and urinary excretion.115 It has been suggested that acidosis depressed hepatic 
uptake of lactate, but increased renal lactate metabolism.115 Any dysfunction of the liver and 
kidney may affect the clearance of lactate.  
Besides, the skeletal muscle seems to play a role in both production and clearance of 
lactate.116 The brain and adipose tissues have shown to contribute in the lactate turnover.116 
LA, a form of metabolic acidosis, develops with the accumulation of lactic acid in blood 
as a cause of acid-base disorder. Clinically, if the blood lactate level reaches to 2-5 mmol/L, it 
is considered as hyperlactatemia; while it is LA when the level is greater than 5 mmol/L with 
pH < 7.35.117, 118 Hyperlactatemia can occur in the setting of intact buffering systems, adequate 
tissue perfusion or oxygenation.117, 119 LA can occur under conditions of excessive tissue lactate 
production or impaired hepatic metabolism of lactate.117, 119  
Traditionally, LA is classified into Type A and Type B LA (Cohen & Woods, 1976)120 
with the main differentiation on whether the tissue oxygen delivery is sufficient or not (Table 
3):118, 121, 122  
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Type A LA refers to circumstances in which there is clinical evidence that tissue oxygen 
delivery is inadequate (anaerobic acidosis). Hypoxaemia, anaemia and shock can lead to type 
A LA.118, 121 When the oxygen supply is insufficient, after glucose being metabolised into 
pyruvate in cytoplasm, the further metabolism of pyruvate inside mitochondria will be slowed 
down, and pyruvate will be converted to lactate (with conversion of nicotinamide adenine 
dinucleotide from reduced form to oxidised form, NADH to NAD+).122, 123 The conversion of 
NADH to NAD+ is important as it regenerates NAD+ needed for glycolysis to continue. This 
process is known as anaerobic metabolism and results in a small net ATP production.114 The 
mitochondrial reactions are unable to have normal function due to inadequate oxygen.  
Type B LA refers to the situations where there is no clinical evidence of insufficient 
tissue oxygen delivery (aerobic acidosis), which is usually caused by (i) underlying disease, 
such as renal failure, liver failure and short-gut syndrome; (ii) drugs or toxicants; or (iii) 
metabolic derangements involving failure to clear lactate.118, 121  
 
Table 3 Classification of lactic acidosis120, 122 
Classifications Causes 
Type A: Clinical evidence of impaired tissue oxygenation 
  Anaerobic muscle activity (increased oxygen demands) 
 Tissue hypoperfusion (decreased oxygen delivery) 
 Tissue hypoxia (decreased available oxygen or carrying capacity) 
Type B: No clinical evidence of impaired tissue oxygenation 
B1  Underlying disease 
 Renal failure; liver failure; malignancy; HIV; short-gut syndrome 
B2  Drugs and toxins 
 Alcohols; beta-agonists; biguanides; carbon monoxide; catecholamines; 
cocaine; cyanide/nitroprusside; isoniazid; linezolid; nalidixic acid; 
nucleoside reverse transcriptase inhibitors; propofol; salicylates; 
theophylline; valproate   
B3  Inborn errors of metabolism 
 Defects in gluconeogenesis, pyruvate dehydrogenase, tricarboxylic acid 
cycle, respiratory chain 
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 Metformin’s effect on lactate level: possible mechanism  
The potential intracellular mechanism of metformin affecting lactate production was proposed 
in the studies which were conducted to discover the mechanism of its glucose lowering effect. 
Early studies suggested that the mechanism of metformin in increasing plasma lactate level 
related to the inhibition of mitochondrial respiration in tissues responsible for lactate 
removal.53, 124, 125 A recent study reported that both acute and chronic metformin treatment 
inhibit mGPD, limiting lactate and glycerol contributions to hepatic gluconeogenesis, which 
resulted in increased lactate levels.55 The inhibition of mGPD halted the glycerophosphate 
shuttle and lead to accumulation of cytosolic NADH, which was unfavourable for the 
conversion of lactate to pyruvate by lactate dehydrogenase. The suggested mechanism could 
explain the potential risk of LA associated with metformin use.  
 
 Treatment for lactic acidosis in metformin-treated patients  
It has been suggested that the mainstay of LA therapy in metformin users was normalising the 
acid-base imbalance and treating the triggering factors for LA.126 Various treatments have been 
used to treat LA in metformin-treated patients; however, there is no consensus in managing in 
this acute condition.  
Administration of bicarbonate and mechanical ventilation have been used to correct 
acidosis.127 But bicarbonate is not routinely recommended, since it may promote lactate 
accumulation and further intracellular acidification.128, 129 Extracorporeal treatment, such as 
haemodialysis and haemofiltration, is quite common to be used in treating LA. A recent 
systematic review129 reported that intermittent haemodialysis was the predominant 
extracorporeal treatment, followed by continuous renal replacement therapy. The ideal 
characteristics of chemicals removable in extracorporeal elimination (i.e. haemodialysis and 
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haemofiltration) are a low volume of distribution, a low percentage of protein-binding and a 
small molecule (which could get through the dialysis membrane).130 Although metformin has 
a small molecular size and is associated with low protein-binding, it has a relatively large 
volume of distribution, which becomes a limiting factor in extracorporeal elimination.126, 129 
However, compared to bicarbonate administration, extracorporeal treatment could correct the 
acidosis more rapidly and be predictable.129 The extracorporeal treatment would also correct 
the electrolyte abnormalities,131 and be beneficial in supporting impaired renal function.130  
 
 Recommendations in product information of metformin and guidelines    
Current official product information recommends that metformin should be avoided or used 
with caution/dosage adjustment in patients with coexisting conditions, as shown in Table 4, 
that are likely to increase the risk of LA. 
Table 4 Contraindications and precautions of metformin 84, 132 
 
29 
 
 Conditions listed in the official product 
information 
Australian Medicines 
Handbook (2012) 
Australian Medicines 
Handbook (online 
2016) 
American Hospital Formulary 
Service (AHFS) Drug 
Information (online 2016) 
Contraindications Acute conditions with potential to alter renal 
function, such as: 
   
 dehydration;  √ √ √ 
 severe infection;  √ and trauma N/A √ 
 shock;  √ √ √ 
 intravascular administration of 
iodinated contrast materials 
√ N/A √ 
Acute or chronic disease which may cause 
tissue hypoxia, such as: 
   
 cardiac failure;  Moderate to severe 
heart failure 
Severe Heart failure Acute heart failure, congestive 
heart failure 
 recent myocardial infarction;  √ √ √ 
 respiratory failure;  √ N/A Respiratory distress 
 gangrene;  N/A N/A N/A 
 shock;  √ √ √ 
 acute significant blood loss;  N/A N/A N/A 
 pulmonary embolism;  √ √ N/A 
 pancreatitis;  N/A N/A N/A 
 sepsis √ √ √ 
Severe hepatic insufficiency (acute alcohol 
intake; alcoholism) 
√ √ √ 
Diabetic coma and ketoacidosis √ √ √ 
Hypersensitivity to the drug N/A N/A √ 
History or states associated with lactic 
acidosis, such as shock or pulmonary 
insufficiency 
√ √ √ 
Renal failure or renal dysfunction (creatinine 
clearance < 60mL/min) 
Contraindicated in 
CrCl < 30 mL/min. 
Contraindicated in CrCl 
< 15 mL/min. 
Contraindicated in eGFR < 30 
mL/min per 1.73m2. 
Lactation  Save in breastfeeding Save in breastfeeding N/A 
Precautions Use in the elderly  √ √ √ 
Discontinued 48 hours before elective major 
surgery and administration of iodinated 
contrast materials 
√ Stop metformin before 
surgery 
√ 
30 
 
Radiological studies using contrast media √ N/A √ 
Surgical procedures √ √ √ 
N/A: information is not available. 
The listed conditions as contraindications and precautions are stated in the official product information of metformin (Glucophage®).
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A number of contraindications to the use of metformin are listed in the product 
information. A few international studies have recently questioned the contraindications to the 
use of metformin, as it was not associated with a significant change in lactate levels in patients 
receiving metformin compared to other antidiabetic agents.133-135 It has been suggested that 
strict adherence to these recommendations may deny a valuable drug to many patients,136 and 
conditions including  myocardial infarction and stable coronary heart failure should not to be 
considered as absolute contraindications to use metformin.133 
The AMH, used as an evidence-based independent medicines reference in the 
Australian healthcare sector, has changed its recommendation to the prescribing of metformin 
since 2014. The previous warning regarding the usage of metformin in AMH was similar to 
that in the product information (Table 4), which recommended that the drug should be 
contraindicated in conditions including respiratory failure, severe infection or trauma, alcohol 
misuse, and moderate to severe heart failure. Overall, the caution of prescribing metformin 
suggested in the current AMH is lower compared to the recommendations in the previous 
versions (before 2014). Currently, it is suggested to use metformin with precautions in 
conditions which may alter renal function (eg dehydration, shock, sepsis) or increase risk of 
tissue hypoxia and acidosis (eg MI, severe heart failure, liver failure, pulmonary embolism, 
ketoacidosis), which may increase the risk of LA. Patients with severe hepatic impairment 
should avoid the use of metformin. Also, elderly patients should use it cautiously; and 
metformin should be stopped before surgery.    
 Dosage reduction of metformin is required in patients with CKD (AMH online 2016): 
a dosage no more than 2,000 mg per day for patients with a CrCl from 60 to 90 mL/min, or 
1,000 mg per day for patients with a CrCl from 30 to 60 mL/min, or 500 mg per day for patients 
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with a CrCl from 15 to 30 mL/min; and metformin is not recommended to be used when the 
CrCl is lower than 15 mL/min.  
The current diabetic management guideline (2014-15)9 from Diabetes Australia states 
that LA is uncommon, which may occur with dehydration and co-existing renal, liver or 
cardiovascular disease. Besides, this guideline recommended that renal impairment (eGFR < 
30 mL/min per 1.73m2) is the only absolute contraindication to metformin.  
Guidelines from other countries also show the concerns of LA to initiate/continue 
metformin, which are similar to the recommendations from AMH and Diabetes Australia. LA 
is the adverse effect which could lead to death, although the incidence is rare. The 
recommendations of “contraindications” of metformin in clinical guidelines from different 
countries varied slightly, mainly due to the quality of the evidence. Majority of the available 
evidence regarding LA in metformin-treated patients are from retrospective designed cross-
sectional studies or case series, the strength of these evidence is being questioned, including 
the design of studies and the number of patients. To date, there is no randomised control trail 
including large number of population with long-term follow-up to investigate the relation 
between metformin and LA; while the contraindications stated in the PI or guidelines could be 
the ethical issue which may it unlikely to conduct a randomised control trial.  
 
   Rationale  
A Cochrane review that included 347 comparative trials and cohort studies revealed no case of 
LA in 70,490 patient-years of metformin use or in 55,451 patients-years in the non-metformin 
group.137 In that review, 57% of the studies excluded patients with renal impairment (defined 
as a creatinine level of greater than 132.6 µmol/L), 46% of cardiovascular disease, 13% of 
pulmonary disease, and 12% of age greater than 65 years. In fact, it is not unusual for patients 
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with diagnosis of T2DM to have other complications (as discussed above); and some of the 
conditions such as renal impairment and heart failure would also be associated with increased 
risk of LA. The contribution of metformin in altering lactate levels in patients with T2DM was 
not clear, especially in those with other underlying clinical conditions.  
In spite of the well-established evidence regarding the benefits of metformin among 
patients with T2DM, the caution of LA may have become a barrier for practitioners to prescribe 
this drug. However, limited studies conducted in Australia have reported on the current usage 
of metformin in practice. It is important to clarify the clinical usefulness of metformin and its 
relation to LA in order to improve the safe use of this drug in all patients with T2DM.  
Thus, this thesis was designed to explore the current usage of metformin in patients 
diagnosed with T2DM in Australia and investigate the cases of LA in metformin-treated 
patients. The specific objectives of the research were:  
 To evaluate the prescribing patterns of metformin in patients with T2DM and to identify 
the potentially inappropriate prescribing of metformin; 
 To identify potential cases of LA related to metformin use; 
 To review and summarise the reported LA cases associated with metformin, and 
explore the potential association between LA and the use of metformin; 
 To compare the lactate levels between patients with T2DM who were treated with 
metformin chronically and those who were not treated with metformin.   
  
 
 
Part B 
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Chapter 2 Metformin usage in type 2 diabetes mellitus: are safety guidelines 
adhered to? 
2 Abstract  
Aim: To (i) evaluate the prescribing patterns of metformin in patients with type 2 diabetes 
mellitus (T2DM) and determine the prevalence of contraindications to its use, especially renal 
impairment, and (ii) identify potential cases of lactic acidosis (LA) related to metformin usage. 
Method: This retrospective study reviewed all patients with a diagnosis of T2DM and taking 
metformin who were admitted to a major teaching hospital over an 8-month period. Data 
including demographics, medical conditions, medications at admission and discharge, and 
relevant pathology results, were extracted from medical records. 
Results: A total of 301 patients (209 medical patients, 92 surgical patients) taking metformin 
were included. According to guidelines, approximately 31% and 21% of patients received 
metformin inappropriately (in the presence of contraindications or in excessive dosage) at 
admission and discharge, respectively. At admission, 65 patients (n=301, 21.6%) on metformin 
had at least one contraindication to its use, and 42 patients (n=254, 16.5%) were prescribed an 
excessive dosage according to their renal function. At discharge, 43 patients (n=301, 14.3%) 
continued on metformin with at least one contraindication and 21 patients (n=191, 11%) 
received an excessive dosage according to their renal function. Four patients had evidence of 
LA (plasma lactate concentration > 5.0 mmol/L and pH < 7.35) without clinical diagnosis. 
Conclusion: Metformin was often used in patients with contraindications to its use, or in higher 
than recommended dosages. Reconsideration of the official prescribing information for 
metformin may be warranted as the risk of harm appears to be very low. 
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 Introduction  
Metformin, a biguanide anti-diabetic agent, is an insulin sensitiser which is used as the first-
line oral medication in the treatment of type 2 diabetes mellitus (T2DM). In Australia, the 
prescribing of metformin has gradually increased,138 largely because of its benefits over other 
anti-diabetic agents. In 2012, diabetes experts in the United States (US) and Europe declared 
that metformin is the first choice for all patients with T2DM.40 The Australian National Health 
and Medical Research Council is considering a similar recommendation.103 In particular, 
metformin does not cause weight gain and is generally associated with a low risk of 
hypoglycaemia. It has been shown that metformin-treated patients experienced significant 
reductions in the risk of myocardial infarction and diabetes-related, as well as all-cause, 
mortality.37 The United Kingdom Prospective Diabetes Study (UKPDS) 10-year follow-up 
demonstrated the significant benefit on cardiovascular disease endpoints and total mortality in 
metformin-treated patients.92 
Despite the evidence base for the benefits of metformin, concerns still remain about its 
side effects, particularly the perceived risks of lactic acidosis (LA),139, 140 especially in patients 
with renal impairment. LA associated with metformin is a rare condition with an estimated 
prevalence of 4.3 cases per 100,000 patient-years.137 However, LA has a 50% fatality rate111, 
141 and hence most current guidelines142-145 recommend that metformin be avoided or used with 
dosage adjustment/ caution in patients with coexisting conditions that are likely to increase the 
risk of LA. Specifically, it is recommended that metformin should be avoided in patients with 
a creatinine clearance (CrCl) less than 30 mL/min146 or estimated glomerular filtration rate 
(eGFR) less than 30 mL/min per 1.73 m2 ,142 severe hepatic impairment, moderate to severe 
heart failure, severe infection, ketoacidosis, and respiratory failure.84 In addition, it is 
recommended that metformin should be used with caution in older people and in patients 
undergoing major elective surgery, with close monitoring of renal function.84 Furthermore, it 
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is also recommended to avoid metformin in patients who are at a high risk of postoperative 
complications, such as sepsis or acute renal failure.41  
In practice, a major dilemma is that strict limitations in metformin usage are presented 
in the official product information (PI) and current guidelines; however, the incidence of LA 
associated with metformin seemingly remains low, including in those whom contraindications 
exist.134, 135 Recent evidence suggested that these contraindications might be overly 
conservative.133 Hence, the main aim of this study was to evaluate the local prescribing of 
metformin in patients with T2DM, and identify potential LA cases related to metformin usage. 
The specific objective was to determine if the prescribing of metformin was in accordance with 
current guidelines, especially in patients in whom renal impairment or contraindications exist. 
 
 Methods  
This retrospective audit included patients with T2DM (International Classification of Diseases 
10th Edition, ICD-10: E11) who were admitted to the Royal Hobart Hospital (RHH), Tasmania, 
between 1st January and 31st August 2012. RHH is the principal referral hospital in Tasmania; 
it has 550 beds serving around 240,000 people in the region. The study was approved by the 
Tasmania Health and Medical Human Research Ethics Committee (Reference number: 
H0012876). 
Medical and surgical patients were included in the study if they met all of following 
criteria (Figure 3): (1) aged over 18 years and had T2DM; (2) were being treated with 
metformin at admission; and (3) had at least an overnight stay in the hospital. Patients with a 
primary diagnosis of acute kidney injury (AKI) were excluded.  In patients who had more than 
one overnight admission during the study period, only the first admission record was included. 
Patients’ medical records both at admission and discharge were reviewed. Data extracted 
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included demographics, medical conditions, medications at admission and discharge, and 
relevant pathology results (e.g. blood glucose, HbA1c, plasma lactate level, pH, eGFR, serum 
creatinine (SCr), albumin, total bilirubin, alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), and gamma-glutamyl transferase (GGT)). The reasons for admission 
identified from the medical record at admission were coded according to the ICD10. The 
medical history and other documentation during hospitalisation were paper based and noted 
without using codes. 
In this study, inappropriate use of metformin was defined as having a contraindication 
to the use of metformin, identified according to: Australian Medicines Handbook (AMH) 2013 
– metformin;146 Diabetes Australia - current guidelines for the management of T2DM;142 
Therapeutic Guidelines (TG);147 and the official PI for metformin (Glucophage®)148 (Table 5). 
Contraindications included: acute significant blood loss, cardiac failure, dehydration, diabetic 
ketoacidosis, gangrene, hepatic dysfunction, pancreatitis, pulmonary embolism, myocardial 
infarction, renal failure, respiratory failure, shock, sepsis, and severe infection.  
Table 5 Contraindications for metformin usage in the official product information, Australian 
Medicines Handbook and the guidelines of Diabetes Australia and Therapeutic Guidelines
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 Conditions listed in the official product 
information (Glucophage®) 
Australian Medicines 
Handbook (2013) 
Diabetes Australia 
(2012-2013) 
Therapeutic 
Guidelines (2013) 
Contraindications Acute conditions with potential to alter renal function, 
such as: 
   
 dehydration;  √ N/A N/A 
 severe infection;  √ and trauma N/A N/A 
 shock;  √ N/A √ 
 intravascular administration of iodinated 
contrast materials 
√ √ √ 
Acute or chronic disease which may cause tissue 
hypoxia, such as: 
   
 cardiac failure;  Moderate to severe heart 
failure 
(Caution) √ 
 recent myocardial infarction;  √ (Caution) √ 
 respiratory failure;  √ N/A √ 
 gangrene;  N/A N/A √ 
 shock;  √ N/A √ 
 acute significant blood loss;  N/A N/A √ 
 pulmonary embolism;  √ N/A √ 
 pancreatitis;  N/A N/A √ 
 sepsis √ N/A √ 
Severe hepatic insufficiency (acute alcohol intake; 
alcoholism) 
√ (Caution) N/A 
Diabetic coma and ketoacidosis √ √ N/A 
Hypersensitivity to the drug N/A √ N/A 
History or states associated with lactic acidosis, such 
as shock or pulmonary insufficiency 
√ √ N/A 
Renal failure or renal dysfunction (creatinine 
clearance < 60mL/min) 
Contraindicated in CrCl < 
30 mL/min 
Contraindicated in 
GFR< 30 mL/min 
Contraindicated in CrCl 
< 30 mL/min 
Lactation  Safe in breastfeeding N/A N/A 
Precautions Use in the elderly  √ √ √ 
Discontinued 48 hours before elective major surgery 
and administration of iodinated contrast materials 
√ √ √ 
Radiological studies using contrast media √ √ √ 
Surgical procedures √ √ √ 
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For the purpose of identifying contraindications, in the absence of a documented 
diagnosis, hepatic dysfunction was defined as biochemical evidence of hypoalbuminaemia and 
abnormal serum levels (greater than the upper level of normal) of at least two of the 
following:149 total bilirubin, ALT, ALP or GGT. Moderate to severe cardiac failure was 
identified by patients’ pharmacological treatment, which included an angiotensin-converting 
enzyme inhibitor or angiotensin receptor antagonist, beta-blocker, and spironolactone with/ 
without digoxin.150 Renal function was identified by calculating the CrCl using the Cockcroft-
Gault equation (CG equation). In cases where CrCl could not be calculated, eGFR was used. 
Metformin was considered contraindicated in patients with a CrCl less than 30 mL/min or 
eGFR less than 30 mL/min per 1.73 m2. The dosage of metformin was considered inappropriate 
in: a dosage higher than 2 gram per day for patients with a CrCl between 60 to 90 mL/min or 
an eGFR between 60 to 90 mL/min per 1.73 m2, or 1 gram per day for patients with a CrCl 
between 30 to 60 mL/min or an eGFR between 30 to 60 mL/min per 1.73m2.146 LA was 
identified when the plasma lactate concentration was > 5.0 mmol/L and pH < 7.35.117, 118  
In patients who underwent planned (elective) surgery, it was also determined whether 
metformin had been discontinued at least 48 hours prior to the surgery and restarted no earlier 
than 48 hours following the surgery, only after the renal function had been re-evaluated and 
found to be normal.148  
The data were summarised and analysed using Microsoft Excel 2010 and Statistical 
Package for Social Sciences (SPSS) for Windows version 20 (SPSS Inc., Chicago, Illinois, 
US).  
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 Results  
A total of 1274 admissions were recorded during the study period with coding as T2DM, and 
the medical records were paper based. After assessment against the study criteria, 301 patients 
were included (Figure 3). The mean ± standard deviation (SD) age of the study sample was 68 
± 12.1 years (range: 24-98 years) and 60% were male (Table 6). The majority of patients 
(n=188, 62.4%) were aged 65 years or over, while 16 % (n=48) were aged 80 years or over. Of 
the 301 patients, 92 patients were admitted for surgery, 47 of whom underwent elective surgery. 
The most common reasons for admission included diseases of the circulatory system (n=87, 
28.9%) followed by diseases of the endocrine system (n=28, 9.3%).  
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Figure 3 Patient selection 
(AKI = acute kidney injury; DMR = digital medical record; RHH = Royal Hobart Hospital; T2DM = type 
2 diabetes mellitus)  
Admission records with T2DM from 1st 
Jan. to 31st Aug. 2012 in RHH (n=1274)
Patients (n=844)
Patients (n=676)
Patients (n=336)
Patients (n=301) 
Medical patients (n=209)
Surgical patients (n=92) 
Excluded: 35 AKI
Excluded: 340 non-
metformin treatment
Excluded:168 not staying 
overnight
Included: the first 
admission record only for 
each patient
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Table 6 Baseline characteristics of the study sample 
Characteristics  Num. of 
patients (n) 
included† 
Value  
Age [Mean ± SD; years]  68 ± 12.1  
Gender [male, %]  182, 60%  
Weight [Mean ± SD; kg]  172 89.8 ± 
26.0 
Height [Mean ± SD; cm] 63 167.4 ± 
10.7 
BMI [Mean ± SD; kg/m2] 63 32.7 ± 
7.8 
HbA1c [Mean ± SD; %] 107 8.6 ± 2.2 
Lactate [Mean ± SD; mmol/L] 114 2.1 ± 1.5 
Serum creatinine (SCr) [Mean ± SD; mmol/L] 282 91 ± 38 
Number of regular medications   7 ± 3  
Number of PRN medications   1 ± 1  
Metformin dosage [Mean ± SD; mg/day] 267 1506.8 ± 
662.1‡ 
Duration of hospitalisation [Median, IQR; days]   5, 2-9 
Reasons of admission (top 
5) [number of patient (%)] 
Disease of circulatory system 
(ICD10-I) 
 87 
(28.9%)  
Endocrine, nutritional and 
metabolic diseases (ICD10-E) 
 28 (9.3%)  
Injury, poisoning and certain other 
consequences of external causes 
(ICD10-S & T) 
 25 (8.3%)  
Neoplasms (ICD10-C & D)  24 (8.0%)  
Diseases of respiratory system 
(ICD10-J) 
 20 (6.6%)  
Other medications for T2DM 
treatment at admission 
[number of patient (%)] 
Insulin   109 
(36.2%)  
Sulfonylureas   96 
(31.9%)  
Thiazolidinediones   15 (5.0%)  
DPP-4 inhibitors  12 (4.0%)  
Acarbose   0 (0)  
Exenatide   5 (1.7%)  
Average num. of medications for T2DM treatment at admission   1 ± 0.5 
Average num. of medications for T2DM treatment at discharge   1 ± 0.5 
† n = 301, unless stated specifically; ‡ The dosage was not recorded in 35 patients.  
IQR = interquartile range. 
 
Of the 301 patients using metformin at admission, 114 patients (37.9%) were prescribed 
metformin as monotherapy for diabetes, 141 patients (46.8%) were on dual therapy, and 43 and 
3 patients (14.3% and 1%) were on triple and quadruple therapy, respectively.  
Overall, metformin was prescribed inappropriately (contraindicated and/ or 
inappropriate dosage) at admission and discharge in 93 patients (n=301, 30.9%) and 63 patients 
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(n=301, 20.9%) respectively. At admission, 65 patients (n=301, 21.6%) had at least one 
contraindication to the use of metformin, with the most common contraindication being cardiac 
failure (Table 7), whilst 42 patients (16.5%) were prescribed an excessive dosage at admission 
based on their renal function (Figure 4Error! Reference source not found.). Out of the 93 
patients who were receiving metformin inappropriately at admission, in 53 patients (57%) 
metformin was continued at discharge despite a contraindication to its use or at an inappropriate 
dose. At discharge, 43 patients (n=301, 14.3%) had at least one contraindication and 21 patients 
(n=191, 11%) received an excessive dosage according to their renal function. In 47 elective 
surgical patients (from a total of 92 surgical patients), metformin was not ceased or re-started 
in accordance with guidelines in 19 (40.4%).  
Table 7 Contraindications to the use of metformin at admission (n=301) 
Contraindications Patient number (%)† 
Cardiac failure (moderate to severe) 18 (6.0)  
Dehydration  2 (0.7) 
Diabetic ketoacidosis 1 (0.3) 
Gangrene  4 (1.3) 
Liver dysfunction 14 (4.6) 
Pancreatitis  5 (1.7) 
Recent myocardial infarction 10 (3.3) 
Renal dysfunction  CrCl (mL/min) <30 8 (2.6) 
eGFR (mL/min per 1.73 
m2) <30‡ 
5 (1.7) 
Respiratory failure 2 (0.7) 
† Some patients had more than one contraindication to use metformin; ‡ Patients reported with eGFR 
are not including those reported with CrCl. 
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Figure 4 Distribution of patients based on different renal function (CrCl or eGFR) for different 
metformin dosages at admission (n=254) and discharge (n=191) 
Adm = at admission; CrCl = creatinine clearance; Dis = at discharge; eGFR = estimated glomerular 
filtration rate; patient number with CrCl: at admission, n = 149; at discharge, n = 138; patient number 
with eGFR: at admission, n = 105; at discharge, n = 53. 
 
 
The dosage of metformin could not be ascertained in some patients due to the missing 
documentation or inconsistent dosage recorded. For the T2DM patients with acute clinical 
condition, surgery or poor blood glucose controlled, insulin would be used during 
hospitalisation, and the dosage of metformin would be uncertain. We have used an additional 
method to identified AKI in case of missing documentation of AKI, with the consideration of 
eGFR and SCr levels of the patients’; however, AKI was being identified and documented 
clearly in the medical notes, there was no additional case of AKI which had to be identified. 
Of 111 patients with a plasma lactate level and metformin dosage being reported at 
admission, 82 patients (n=111, 73.9%) had a value within the normal range (less than 2.4 
mmol/L) and 25 patients (n=111, 22.5%) had a level between 2.4 and 5.0 mmol/L. Four patients 
had a plasma lactate level higher than 5.0 mmol/L and pH less than 7.35, but none of them had 
a recorded diagnosis of LA (Table 8). All 4 patients had at least one comorbidity (seizure, 
cardiac arrest or sepsis), that could have been associated with LA.36 One patient (Patient 4, 
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Table 8Table 8) died within 24 hours after admission, with sepsis and non-ST segment 
myocardial infarction (NSTEMI) as the cause of death. The other three patients had their lactate 
level managed back to the normal range soon after admission. In all three patients, metformin 
was withheld during hospitalisation and re-commenced at discharge. 
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Table 8 Patients reported with increased lactate level 
Patient 
no. 
Age 
(years) 
Gender  pH Lactate 
(mmol/L) 
SCr 
(µmol/L) 
eGFR (mL/min 
per 1.73 m2) 
Metformin at 
admission/discharge 
(mg/day) 
Other 
conditions 
Outcome  
1 68 M 7.29 10.2 83 90 2000/1500 Seizure Discharged  
2 69 M 7.33 5.1 91 72 2000/2000 Ischaemic heart 
disease 
Self-
discharged 
3 55 M 7.14 6.9 190 32 2000/1000 Cardiac arrest Discharged 
4 87 F 7.29 10.1 156 27 500† Sepsis, NSTEMI Died  
eGFR = estimated glomerular filtration rate; F = female; M = male; NSTEMI = non-ST segment myocardial infarction; SCr = serum creatinine; † Patient 4 died 
within 24 hours after admission. 
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 Discussion  
Approximately 31% and 21% of patients were prescribed metformin inappropriately at 
admission and discharge, respectively. There were 4 patients identified with LA according to 
biochemical definition in our study, but 3 patients survived after the emergency admission and 
were continued with metformin at discharge. The comorbidities in these cases were considered 
more likely to account for the occurrence of LA. Our finding of metformin often being 
prescribed in patients with contraindications to its use was reported in other studies.151-154 The 
Fremantle Diabetes Study (FDS) in Western Australia found that 23.1% of patients receiving 
metformin had one or more contraindications to its use, and suggested that metformin did not 
increase the risk of LA.108 They reported 3 confirmed cases of LA associated with metformin 
usage. Those three patients also had at least one significant comorbidity that could be 
associated with LA. Although the criteria included in the FDS were not exactly the same as 
this study, major contraindications to its use such as renal impairment and cardiac failure were 
included in both studies. The major contraindication was cardiac failure in our patients, while 
renal impairment was the main issue in the FDS.  
The association between metformin and LA could be overemphasised. In addition, it 
has been reported that diabetes per se, rather than metformin therapy, was more likely to be the 
major risk factor in developing LA.155-157 Compared with non-diabetic patients, micro- or 
macrovascular disease in diabetic patients may also contribute to the development of acidosis, 
potentially by causing tissue hypoxia.158   
Metformin seems generally safe for use in most patients, even in those with 
contraindications. Scheen and Paquot133 recently published a review suggesting that conditions 
such as mild-to-moderate chronic kidney disease and stable congestive heart failure should not 
be considered as contraindications to the usage of metformin. In our study, metformin was 
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continued at discharge despite a contraindication to its use, or at an inappropriate dose, in 57% 
patients who were prescribed the drug inappropriately at admission. These patients may have 
been admitted to the hospital because of reasons unrelated to diabetes. Doctors, understandably, 
might have been reluctant to make changes to the therapy if the patients’ blood glucose levels 
were well controlled. A retrospective study in Canada found that 58 patients (28% of total) 
who were dispensed metformin had at least one contraindication, which included congestive 
heart failure, hepatic dysfunction and renal insufficiency; 50 of these 58 patients (86%) were 
continued on metformin after their contraindication(s) were identified.159 
Renal impairment is one of the major contraindications to the use of metformin as it is 
excreted unchanged through the kidney and could accumulate in renal impairment, thereby 
increasing the risk of LA.126 In addition, lactate metabolism and excretion through the kidneys 
may be reduced in patients with renal impairment,115 further increasing the risk of LA. 
Although the AMH and guidelines in Australia do not have the same recommendation as the 
PI, that metformin should be avoided in CrCl less than 60 mL/min, dosage reduction according 
to renal function is recommended. LA may be more likely in patients with AKI, rather than 
chronic kidney disease.126, 160, 161 Patients with a diagnosis of AKI were not included in this 
study. Metformin was used in 13 patients with CrCl < 30 mL/min or eGFR < 30mL/min per 
1.73m2 at admission (Figure 4). One of these had a lactate level of 10.1 mmol/L (sepsis was 
more likely to be responsible in this case; Table 8).  
Similar results were found in studies elsewhere162, 163 suggesting that metformin was 
frequently used in patients with renal impairment without developing LA. A cohort study on 
almost 52,000 T2DM patients in Sweden showed that metformin as monotherapy, compared 
to other oral anti-diabetic agents, was associated with a reduced risk of acidosis/ serious 
infection, and all-cause mortality in patients with an eGFR between 45 and 60 mL/min per 
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1.73m2. Similar results were also seen in patients with an eGFR between 30 and 45 mL/min 
per 1.73 m2.164 
Recent studies have suggested that metformin could be used safely in patients with 
renal impairment by controlling its plasma concentration and not exceeding 5 mg/L.165, 166 It 
was shown that the peak plasma metformin level would not exceed 5 mg/L in 95% of patients 
if the maximum daily dosage was restricted to 500, 1000, 2000 and 3000 mg in patients with 
CrCl of 15, 30, 60 and 120 mL/min, respectively. In addition, it was found that the plasma 
lactate did not have a significant correlation with either metformin plasma concentration or 
dosage.166 However, clinical outcome studies regarding the safety of metformin in patients with 
renal impairment are lacking. It has been suggested that it would be more appropriate to adjust 
the dose of metformin according to renal function and monitor closely for any side effects 
rather than ceasing metformin therapy.167  
When interpreting the findings of this study some limitations should be considered. The 
retrospective nature of the study has rendered the data incomplete. We were only able to 
calculate CrCl in around half of the patients due to missing body weight, which might have led 
to inaccurate estimation of renal function. The eGFR levels were recorded from the laboratory 
results in the hospital and not adjusted to body surface area. In cases without complete 
documentation of a medical history, hepatic dysfunction and cardiac failure were identified 
according to their medications or pathology results. For example, patients in this study 
identified with having hepatic dysfunction may not necessarily have clinical hepatic 
dysfunction and the usage of metformin may still be appropriate. In addition, we were unable 
to identify the severity of hepatic dysfunction and it is important to note that severe hepatic 
dysfunction may still be a valid contraindication for the use metformin.133 Similarly, we could 
not identify the severity of patients’ cardiac failure. However, it is a standard approach to use 
the standard drug therapy for moderate to severe heart failure as an indicator, as these drugs 
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would not be used in combination for other indications.150 168 Given that recent clinical trials 
have shown benefits in patients with cardiovascular disease and cardiac failure,39 it might be 
appropriate to continue metformin in patients who have well controlled cardiac failure rather 
than ceasing it. 
 
 Conclusion  
Metformin was prescribed inappropriately in almost one third of the study patients, according 
to the current PI and guidelines. However, metformin appeared generally safe to be used in 
these patients, with no increased risk of acidosis. Cases of elevated lactate levels were 
identified, but these patients were also found to have other underlying clinical conditions 
associated with an increased risk of LA.  
Together with previous findings, the evidence presented in this study suggests that the 
cautions/ contraindications stated in the PI and guidelines seem overly conservative including 
the attention on metformin-associated LA. Further clinical outcome studies in specific 
population groups are warranted to guide prescribers and the official PI should be reassessed 
and updated to reflect the current clinical practice. Thus, considerably more patients may be 
considered for treatment with metformin given its substantial benefits. 
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Chapter 3 Metformin utilisation in Australian community and aged care 
settings 
3 Abstract  
Objective: The objective of this study was to: i) evaluate the potentially inappropriate 
prescribing (PIP; defined as the use of metformin in the presence of contraindications and/or 
use in excessive dosage based on the renal function) of metformin in people receiving 
medication reviews in Australia; and ii) identify the predictors for PIP of metformin. 
Method: Retrospective study of patients taking metformin through a large medication review 
database, containing records between January 2010 and June 2012. Data, including 
demographics, medical conditions, medications and relevant pathology results, were extracted 
for analysis. Multivariate logistic regression analysis was used to detect risk factors for PIP of 
metformin. 
Results: Medication reviews pertaining to 6,386 patients who received Home Medicines 
Reviews (HMRs, n=5,327) or Residential Medication Management Reviews (RMMRs, 
n=1,059) were included in this study. Overall, there were 12.9% (n=685) of patients in the 
HMR group and 17.4% (n=184) of patients in the RMMR group who had PIP of metformin. 
Multivariate logistic regression showed age, gender and type of medication review service as 
the significant (p<0.05) independent risk factors for PIP of metformin. 
Conclusion: Metformin was often used in patients with contraindications, or in higher than 
recommended dosages in patients with renal impairment. Given the recent debate in the 
literature about the role of metformin in the presence of contraindications, a detailed 
prospective study in patients with contraindications and its association with lactic acidosis is 
warranted to establish the way in which metformin is to be used in these patients.  
53 
 
 Introduction 
Metformin is a biguanide that acts as an insulin sensitiser and is commonly used in the 
treatment of type 2 diabetes mellitus (T2DM). Metformin is the first choice for the treatment 
of T2DM in the United States and Europe.40 Similarly, the Therapeutic Guidelines in 
Australia169  and by Diabetes Australia142 also recommend metformin as the first drug of choice 
for the treatment of T2DM. Patients taking metformin have a significantly reduced risk of 
myocardial infarction, as well as both diabetes-related and all-cause mortality.37 Compared to 
most other medications used to treat T2DM, metformin does not cause weight gain, and is 
generally associated with a low risk of hypoglycaemia.40  
Despite the evidence-based benefits of metformin, concerns regarding the risks of lactic 
acidosis (LA) remain.140 The mechanism of metformin-associated LA is complex and 
incompletely understood.126 The clinical conditions that contraindicate metformin use are 
considered as risk factors for LA. For example, in patients with renal impairment, metformin 
may accumulate because the drug is mainly excreted by the kidney.115, 139 According to the 
Australian product information (PI; Glucophage®, Diabex® XR), metformin is also 
contraindicated in conditions that may be associated with tissue hypoxia, such as heart failure, 
respiratory failure, or pancreatitis.  
Few studies internationally have recently questioned the contraindications to the use 
metformin as it was not associated with a significant change in lactate levels compared to other 
antidiabetic agents.133-135 A recent study conducted in hospitalised patients reported that 
metformin was frequently prescribed despite the presence of contraindications.170 However, 
data on the utilisation of metformin in Australian community and aged care settings is limited. 
Hence, the main objective of this study was to evaluate the use of metformin through a large 
sample of Home Medicines Review (HMR) and Residential Medication Management Review 
(RMMR) records in Australia, with a particular focus on assessing its use in patients with 
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apparent contraindications and in excessive dosage. The secondary objective was to identify 
the predictors for potentially inappropriate prescribing (PIP) of metformin (defined as the use 
of metformin in the presence of contraindications and or use in excessive dosage based on the 
renal function).  
 
 Methods 
This retrospective study involved the collection of de-identified data from HMR and RMMR 
cases. These two Government-funded services represent a key strategy for achieving quality 
use of medicines in Australia. HMR is a community-based collaborative service provided by 
general practitioners (GPs) and accredited pharmacists. RMMR is available to all permanent 
residents of Australian Government-funded aged care homes.171 Both services comprise of: i) 
GP referral of a patient or resident; ii) accredited pharmacist visit (at home in the case of an 
HMR), including an interview of the patient or resident and review of medications to ascertain 
a comprehensive medication profile; iii) discussion by GP and pharmacist to develop a 
medication management plan based on findings and recommendations; and iv) consultation 
with the patient or resident to obtain agreement to the medication management plan.   
Medscope™ is an IT company providing a decision support solution for accredited 
pharmacists performing medication reviews (HMRs and RMMRs). Approximately 15% of 
medication reviews in Australia are performed with the assistance of this online system which 
suggests that the sample would be likely to represent the population who receive medication 
reviews. The Medscope™ database contains approximately 40,000 medication review records 
for the period between January 2010 and June 2012. T2DM and metformin were the search 
terms used in identifying the patients to include in this study. All patients aged 18 years or 
more were included and no additional exclusion criteria was applied. Due to the de-identified 
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nature of the data collected, the study was exempted by the Tasmania Health and Medical 
Human Research Ethics Committee. 
Patients’ de-identified details, which included demographics, medical conditions, 
pathology test results and medications, were extracted. The medical conditions were coded 
according to the International Classification for Primary Care, second edition (ICPC-2), and all 
medications were coded according to the Anatomical Therapeutic Chemical Classification 
System.172  
Potentially inappropriate use of metformin was defined as having a contraindication to 
the use of metformin or an excessive dosage with respect to creatinine clearance (CrCl) or 
estimated glomerular filtration rate (eGFR). Renal function was determined by calculating the 
CrCl using the Cockcroft-Gault equation or the eGFR using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation. In cases where CrCl could not be calculated 
(i.e. no documented body weight), the eGFR was used to identify PIP. We included moderate 
to severe heart failure, hepatic dysfunction, pancreatitis and renal failure (CrCl < 30 mL/min 
or eGFR < 30 mL/min per 1.73 m2) as contraindications.148, 173, 174 In the absence of a 
documented diagnosis, hepatic dysfunction149 was defined as biochemical evidence of 
hypoalbuminaemia and abnormal serum levels of at least two of the following: total bilirubin, 
alanine aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase. 
For the purpose of evaluating the inappropriate dosage of metformin taken in patients 
with renal impairment, the recommendations in Australian Medicines Handbook (AMH) were 
used.174 The dosage of metformin conventional tablet was considered inappropriate in: i) a 
dosage higher than 3,000 mg per day in all the patients; ii) a dosage higher than 2,000 mg/day 
for patients with a CrCl 60-90 mL/min or an eGFR 60-90 mL/min per 1.73 m2; and iii) a dosage 
higher than 1,000 mg/day for patients with a CrCl 30-60 mL/min or an eGFR 30-60 mL/min 
per 1.73m2. For patients taking metformin controlled-release tablets, it was considered 
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inappropriate in: i) a dosage higher than 2,000 mg per day; and ii) a dosage higher than 1,000 
mg per day in patients with a CrCl 30-60 mL/min or an eGFR 30-60 mL/min per 1.73m2. 
Potential under dosing of metformin was identified based on the documented glycated 
haemoglobin (HbA1c). Metformin was considered to be potentially under-dosed (prescribed 
less than its maximum dose with consideration of the renal function): i) if the patient’s age was 
< 75 years and the HbA1c > 7.0% (53 mmol/mol), in the absence of any contraindications; or 
ii) if the patient’s age was > 75 years and the HbA1c > 8.0% (64 mmol/mol),175, 176 in the 
absence of any contraindications. 
The data were summarised and analysed using Microsoft Access 2010 and the IBM 
SPSS Statistics for Windows, Version 20 (IBM Corp., Armonk, NY, US). Backward logistic 
regression analysis was used to identify the independent risk factors for PIP of metformin. 
Variables whose probability (p) values were ≤0.10 in the univariate analysis were entered into 
the logistic regression model. An alpha of <0.05 was used to test the statistically significance. 
Backwards logistic regression was chosen as it starts with all potential predictors 
(significant in univariate analyses) included in the model and is a standard approach. Then it 
tests whether any of these predictors can be removed from the model without having a 
substantial effect on how well the model fits the observed data.  
 
 Results 
A total of 6,386 patients were included in this study: 5,327 HMRs (49.2% male) and 1,059 
RMMRs (39.1% male). The mean age of the patients was 69.7 ± 11.1 and 81.6 ± 8.3 years for 
HMRs and RMMRs, respectively (  
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Table 9). The majority of patients were older than 75 years (35.8% of HMRs and 79.9% 
RMMRs).    
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Table 9 Summary patient characteristics 
 HMR (n = 5,327) RMMR (n = 
1,059) 
Gender (male; %) 49.2  
(n = 2,620) 
39.1  
(n = 414) 
Age (mean ± SD; years) 69.7 ± 11.1  
(n = 5,297) 
81.6 ± 8.3  
(n = 1,058) 
 < 65 years (%) 30.0 
(n=1,598) 
3.4 
(n=36) 
 65 to < 75 years (%) 34.2 
(n=1,824) 
16.7 
(n=177) 
 ≥ 75 years (%) 35.8 
(n=1,905) 
79.9 
(n=846) 
Weight (mean ± SD; kg) 90.3 ± 32.1  
(n = 1,818) 
72.9 ± 18.2  
(n = 688) 
BMI (mean ± SD) 33.09 ± 7.0  
(n = 447) 
30.0 ± 7.3  
(n = 22) 
HbA1c (%) 7.0 ± 1.4  
(53 mmol/mol) 
(n=1,854) 
6.8 ± 1.4  
(51 mmol/mol) 
(n=222) 
Dosage of metformin (mean ± SD; mg/day)    
 Metformin conventional tablet 1651.5 ± 735.6 
(n=3,205) 
1347.3 ± 650.8 
 (n=688) 
 Metformin controlled release 
tablet 
1214.5 ± 619.2 
(n=2,055) 
1060.3 ± 541.0 
 (n=369) 
eGFR (mean ± SD; mL/min per 1.73 m2)* 68.8 ± 20.2 
(n = 1,624) 
57.7 ± 20.9  
(n = 225) 
Stages of Chronic 
Kidney Disease 
 
 
 
 
 
 
Stage 1: ≥ 90 mL/min per 1.73m2 
(%) 
18.0 
(n=293) 
8.0  
(n=18) 
Stage 2: 60-89 mL/min per 1.73m2 
(%) 
46.6 
(n=757) 
32.9 
(n=74) 
Stage 3a: 45-59 mL/min per 
1.73m2 (%) 
21.7 
(n=353) 
28.9 
(n=65) 
Stage 3b: 30-44 mL/min per 
1.73m2 (%) 
12.0 
(n=195) 
23.1 
(n=52) 
Stage 4: 15-29 mL/min per 1.73m2 
(%) 
1.6 
(n=26) 
7.1 
(n=16) 
Stage 5: < 15 mL/min per 1.73m2 
(%) 
0 0 
CrCl (mean ± SD; mL/min)† 73.0 ± 22.0  
(n = 901) 
52.9 ± 24.9  
(n = 124) 
Contraindications (%)   7.5 
(n=398)  
14.4 
(n=152) 
 Pancreatitis (%) 0.4 
(n=22) 
0.7  
(n=7) 
 Hepatic dysfunction (%) 0.2 
(n=9) 
0.2 
(n=2) 
 Heart failure (%) 6.4 
(n=341) 
11.7 
(n=124) 
 CrCl < 30mL/min or eGFR < 
30mL/min/1.73m2 (%) 
0.7 
(n=39) 
2.6 
(n=28) 
Inappropriate dosing (%) 20.2 
(n=329/1,624) 
20.0 
(n=45/225) 
Inappropriate prescribing (%) 12.9 
(n=685) 
17.4 
(n=184) 
*The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation, and the classification is according to guideline of Kidney Health Australia; †The CrCl 
was calculated using the Cockcroft-Gault equation; BMI = body mass index; CrCl = creatinine 
clearance; eGFR = estimated glomerular filtration rate; HbA1c =glycated haemoglobin; HMR = 
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Overall, there were 12.9% (n=685) and 17.4% (n=184) of patients receiving HMR and 
RMMR, respectively, had PIP of metformin. There were 398 (n=5,327; 7.5%) patients in the 
HMR group and 152 (n=1,059; 14.4%) patients in the RMMR group who had at least one 
contraindication to the use of metformin. Heart failure was the most common contraindication 
in both groups. Based on renal function (either CrCl or eGFR), 329 patients (n=1,624; 20.2%) 
in the HMR group and 45 patients (n=225; 20.0%) in the RMMR group were taking an 
excessive dosage. In addition, 37 patients in the HMR group and 3 patients in the RMMR group 
were receiving metformin higher than the maximum daily dosage (more than 3,000 mg per day 
in conventional formula or 2,000 mg per day in extend-released formula). Potential under-dose 
of metformin was identified through the documented HbA1c in 49 patients in the HMR group 
(n=672; 7.3%) and 1 patient in the RMMR group (n=74; 1.3%).  
Table 10 Association with PIP of metformin 
 
*Type of medication management: Home Medicines Reviews or Residential Medication Management 
Reviews 
 
All study variables except for the ones used to define PIP of Metformin were entered 
in a backward logistic regression model. The backward logistic model proposed a three 
variables model after three steps removing weight and HbA1c status. Increasing age, female 
gender and patients living in residential aged care facilities (receiving RMMR) were more 
likely to be prescribed metformin inappropriately (Table 11Error! Reference source not 
Home Medicines Review; RMMR = Residential Medication Management Review; SD = standard 
deviation; T2DM = type 2 diabetes mellitus. 
 
Variables p value 
Age (years) <0.01 
Gender  0.06 
Type of medication management* 0.02 
Weight (kg) 0.28 
HbA1c (%) 0.11 
60 
 
found., Both forward and backward logistic regression have been performed and no difference 
in the significance of results shows in these two regression models). 
Table 11 Predictors for potential inappropriate prescribing of metformin from multivariate 
logistic regression analysis 
 PIP of metformin 
Odds ratio (95% CI) 
p value 
Age  1.07 per year [1.04-1.09] <0.01 
Female 1.50 [1.05-2.14] 0.02 
Patients receiving RMMRs 1.87 [1.10-3.18] 0.02 
RMMR = Residential Medication Management Review 
 
 Discussion 
Our finding of metformin often being prescribed in patients with contraindications to its use 
has been reported in overseas studies.153, 154 We previously found approximately one-quarter 
of patients admitted to hospital received metformin inappropriately with contraindications or 
in excessive dosage.170 Emilie-Smith et al. reported 24.5% of people admitted to hospital 
receiving metformin had contraindications to its use.177 Consistent with previous studies, heart 
failure was found as the most common contraindication in patients receiving metformin. Recent 
studies suggested that metformin may not be absolutely contraindicated and could be beneficial 
in these patients.97, 178, 179 A recent systematic review and meta-analysis suggested that in 
patients with comorbid heart failure and diabetes, metformin was the only anti-diabetic agent 
which has not been associated with harm.180 It has also been suggested that physicians are 
increasingly disregarding the contraindications to metformin and the incidence of LA has not 
increased, so metformin may be safe even in patients with “contraindications”.137, 140 
Renal impairment is also one of the major contraindications to the use of metformin as 
it is excreted unchanged through the kidneys and could accumulate in renal impairment, 
thereby increasing the risk of LA.126 However, metformin was found to be used commonly in 
patients with renal impairment,170, 181, 182 in both community and hospital settings. In our study 
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approximately 35% of the patients in the HMR group and 60% of the patients in the RMMR 
group were prescribed with metformin while having an eGFR < 60 mL/min per 1.73m2. Of 
note that in 21.8% of patients in the HMR group and 27.1% of patients in the RMMR group 
were receiving metformin inappropriately based on their renal function.  
The British National Institute for Health and Care Excellence (NICE) recently 
suggested that metformin can be used in patients with eGFR 45-60 mL/min per 1.73m2.183 The 
AMH recommends using metformin with dosage adjustment in patients with CrCl 30-90 
mL/min and, while being contraindicated in patients with CrCl < 30 mL/min. Besides, Ekström 
and colleagues164 evaluated the effectiveness and safety of metformin in more than 50,000 
Swedish men and women with T2DM aged between 40 and 85 years, and found no increased 
risks of all-cause mortality, acidosis and/or serious infection, or cardiovascular disease in 
patients with eGFR 30-45 mL/min per 1.73m2. It has been recently suggested that metformin 
may be tolerated at eGFR of < 30mL/min per 1.73m2,136, 184 particularly in patients with stable 
CKD with no other significant liver or respiratory disease, as CKD may not be a causative 
factor for LA but a co-precipitating factor.184 Davoren recently proposed several changes to the 
current PI for metformin,136 including: metformin might be used in selected patients with CrCl 
< 30 mL/min, where its use is closely supervised; and metformin could be continued despite 
some of the contraindications in the current PI, as long as the dose is reduced in these patients 
and stopped during acute illness.  
The results from the logistic regression analysis showed that patients in the RMMR 
group were more likely to have PIP of metformin compared to the patients receiving HMRs. 
In this sub-analysis, more patients with heart failure and renal impairment in RMMR group 
were prescribed with metformin compared to those who received an HMR. In addition, older 
people were more likely to receive PIP of metformin. This is not surprising given that older 
people often suffer from multiple comorbidities and are likely to have more contraindications 
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to the use of metformin. However, many clinicians prefer using metformin in older people 
because of its benefits and also relatively low risk for hypoglycaemia.185 The majority 
(approximately 80%) of patients in the RMMR group were ≥ 75 years. It is interesting to note 
that prior to 2010 the AMH recommended avoiding metformin in people aged greater than 85 
years, but since then this recommendation has been revised to be used with caution. Similarly, 
the PI also recommends avoiding titration of metformin to its maximum dose in older people 
and avoiding use in people > 80 years unless normal renal function has been established. 
However, the literature on metformin usage in elderly is very limited, especially in people over 
85 years. Future studies should evaluate in detail the benefits and safety of metformin in this 
age group. 
It is interesting to note that in our study PIP of metformin was also identified in some 
patients in the absence of contraindications, i.e. prescribing of metformin beyond the maximal 
recommended dosage (3,000 mg per day) and potential under dose of metformin with respect 
to HbA1c. However, we did not have details of patients’ compliance; making it hard to 
accurately establish the extent of under dosing of metformin based on HbA1c. Besides, the 
target of HbA1c varies depending on each individual, especially in elderly patients.    
When interpreting the findings of this study some limitations should be considered. The 
data is incomplete due to the retrospective nature of this study. The sample in this present study 
represents the population with diabetes receiving these two services in Australia and may not 
represent the general population with diabetes. It is possible that patients referred for these 
services have more co-morbidities, multiple medications and are at a higher risk of drug-related 
problems compared to the general population with diabetes. In addition, we only included heart 
failure, hepatic dysfunction, pancreatitis and renal failure as contraindications to metformin.  
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From the database it was impossible to establish the severity of heart failure and our 
study may have overestimated the PIP of metformin with respect to moderate to severe heart 
failure. Furthermore, weight was not recorded in all patients and we therefore used the eGFR 
to identify PIP for patients in whom weight was not recorded. The interaction between variables 
included in the logistic regression model was not assessed in this study; therefore, for example, 
it is unknown whether the effect of age on the PIP of metformin is influenced by the gender. 
Although recent recommendations from the Food and Drug Administration and the National 
Institute of Diabetes and Digestive and Kidney Diseases suggest that eGFR can be used for 
drug dosing,186, 187 the AMH provides recommendations based on the CrCl as calculated by the 
Cockcroft-Gault equation.    
 
 Conclusion  
Despite the limitations stated above, metformin was found to be often prescribed 
inappropriately; both in excessive dosage and in patients with contraindication(s). Currently, 
clinicians continue to prescribe metformin even in the presence of contraindications due to the 
substantial evidence of metformin benefit in patients with diabetes. However, given the recent 
debate in the literature about the role of metformin in the presence of contraindications a 
detailed prospective study in patients with contraindications in association with LA is 
warranted to establish the way in which metformin is to be used in these patients. 
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65 
 
Chapter 4 Adverse event notifications implicating metformin with lactic 
acidosis in Australia 
4 Abstract 
Objective: To summarise the reported lactic acidosis cases associated with metformin from the 
Australian Therapeutic Goods Administration (TGA) and estimate the incidence of metformin-
associated lactic acidosis (MALA) in Australia. 
Method: All “lactic acidosis” cases associated with metformin and reported to the TGA 
between January 1971 and October 2014 were included. Data extracted included patient 
demographics, medical history and co-existing conditions, metformin dosage and relevant 
pathology results. 
Result: A total of 152 cases of suspected MALA were included in this study. For 20 patients 
the outcome was unknown, and of the remaining 132 patients, 23 patients (17.4%) were 
reported as deceased. Plasma lactate levels were higher in non-survivors (p=0.02). Of 132 
patients, 35 patients (26.5%) were reported to have at least one pre-existing contraindication to 
the use of metformin; this proportion was not different between patients who died or survived. 
Renal impairment was the most common contraindication. Approximately 75% of patients 
were reported to have at least one clinical condition which might cause acidosis. Metformin 
dosage, plasma lactate and serum creatinine were not correlated. Based on the cases reported 
to the TGA, the incidence of MALA in Australia was estimated to be 2.3 (95% CI, 1.5-3.1) 
cases per 100,000 patient-years between 1997 and 2011.   
Conclusion: Pre-existing clinical conditions, such as renal impairment, and acute illnesses 
associated with lactic acidosis were frequently reported in the cases of MALA. The estimated 
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incidence of MALA was lower than in most previous studies in other countries, probably due 
to the nature of spontaneous reports to the TGA.  
 
 Introduction 
Metformin is recommended as the first-choice for pharmacological treatment of type 2 diabetes 
mellitus (T2DM) in Australia9 and many other countries.40, 183 A wide array of benefits have 
been attributed to metformin. These include attenuation of abnormal glucose metabolism, 
weight loss, improvement in components of the metabolic syndrome, lipid lowering properties 
and cardiovascular protection.37, 184, 188, 189 A common clinical conundrum facing practitioners 
treating patients with T2DM is the potential risk of lactic acidosis (LA), which has a mortality 
rate of 30%-50%.190, 191 Metformin is implicated with type B2 LA (a form of LA caused by 
drugs or toxins with no clinical evidence of insufficient tissue oxygen delivery) according to 
the Cohen and Woods (1976) classification. The incidence of metformin-associated lactic 
acidosis (MALA) has been estimated in the United States (US) and European countries,26, 108, 
109, 192 but there is limited data in Australia. The reported incidence of MALA has varied, 
ranging from 1.5 to 530 cases per 100,000 patient-years; in comparison, LA has been reported 
with an incidence of 9.7 to 16.7 per 100,000 patient-years in individuals with diabetes not 
taking metformin.26, 107, 109, 111, 192, 193 Given the benefits of metformin and the relatively rare 
incidence of MALA, many recent publications have supported its expanded use, even in cases 
where it would be officially contraindicated, particularly as the available data suggest that 
lactate levels and the risk of LA do not differ appreciably in patients taking this drug versus 
other glucose-lowering agents.134, 135, 137, 140  
In Australia, adverse effect (AE) reporting is one of the main pathways for the 
Therapeutic Goods Administration (TGA) to monitor the safety of medicines. All reports are 
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analysed and checked by medical experts before becoming publicly accessible. These AE cases 
are reported mostly by pharmaceutical companies, as well as voluntarily by hospitals, general 
practitioners, State and Territory Health Departments, consumers and community pharmacists. 
The objective of this study was to: i) summarise the cases of LA related to metformin usage 
reported to the TGA and evaluate other medications and clinical conditions reported in these 
cases; and ii) estimate the incidence of MALA in Australia. 
 
 Methods 
The terms “metformin” and “lactic acidosis” (defined by the Medical Dictionary for Regulatory 
Activities; MedDRA194) were used to search the medication AE reports from the TGA. All 
cases reported from 1971 to October 2014 were obtained. There were no additional exclusion 
criteria applied in this study. 
Data extracted included patient demographics, medical history including risk factors 
for LA, metformin daily dosage, other medications including documented therapy for acidosis 
(inotropes, mechanical ventilation and renal replacement therapy), relevant pathology results 
(e.g. lactate level, pH and creatinine) and description of the AE (the medical conditions or AEs 
were defined by MedDRA). 
The medicines implicated in drug-induced LA were identified according to the Cohen 
and Woods classification type B2.118, 121 The following medicines were included: isoniazid, 
linezolid, theophylline, valproate, spironolactone, beta-agonists, and anti-retroviral agents.    
The data were summarised and analysed using Microsoft Access 2010 and the IBM 
SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, US). Independent t-tests 
or Mann-Whitney U tests were performed for comparing the continuous variables between 
68 
 
patients who died and survived. Spearman tests were used to explore the possible correlation 
between metformin daily dosage and plasma lactate level, plasma pH and serum creatinine. 
Pearson chi-square tests or Fisher’s exact tests were performed for the categorical variables. 
An alpha of < 0.05 was considered statistically significant. 
The estimated incidence of MALA was calculated using the average annual number of 
cases reported to the TGA from 1997 to 2011 (the annual numbers of community prescriptions 
of metformin reported in the Australian Statistics on Medicines were only available for this 
period), divided by the estimated annual number of patients taking metformin in these 15 years. 
The estimated patient number was calculated using the annual numbers of community 
prescriptions (i.e. subsidised and non-subsidised) of metformin reported in the Australian 
Statistics on Medicines195 divided by twelve, assuming each patient had one prescription each 
month based on the standard dosage and pack quantities subsidised through the Australian 
Pharmaceutical Benefits Scheme.  
 
 Results 
A total of 152 cases of LA potentially associated with metformin use were reported to the TGA 
during the study period [Due to the incomplete documentation in some of the case reports, the 
individual variable reported in the Results section were based on the actual available number 
of cases for each variable, number of patient (n) is not always equal to 152]. The median age 
of patients reported in the case reports was 68 years (IQR: 63-74 years, n=150 where age was 
documented) and 42.8% (n=152) were men. Patients had been treated with metformin in a 
mean (standard deviation, SD) daily dose of 2,124 (± 966) mg (n=134; six patients had a dose 
more than 3,000 mg per day, including intentional overdose). The mean lactate level was 12.0 
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(± 6.0) mmol/L, which was reported in 74 patients; the pH was reported in 51 cases (47 of these 
cases had noted lactate level).  
The annual numbers of community prescriptions of metformin reported in the 
Australian Statistics on Medicines increased gradually from 1997 to 2011, while the reported 
number of MALA cases varied each year. Overall, the estimated incidence of MALA was 2.3 
(95% CI, 1.5-3.1) cases per 100,000 patient-years (ranged between 0.5 and 6.8 cases per 
100,000 patient-years) between 1997 and 2011. 
For 20 patients the outcome was unknown. Table 12 shows the comparison between 
patients who survived and died. Of the 132 patients, 23 patients (17.4%) were reported as 
deceased. Plasma lactate levels were higher in patients who died (p=0.02,Error! Reference 
source not found.), but there was no significant difference found in age, plasma pH, serum 
creatinine or metformin daily dosage. Metformin daily dosage, plasma lactate, plasma pH and 
serum creatinine were not correlated, except for the plasma lactate and pH (p<0.01, Spearman 
r=-0.66). 
Of the 132 cases, 35 cases (26.5%) were reported to have at least one contraindication 
to the use of metformin according to the medical history Table 12, and this proportion was not 
significantly different between patients who survived and died (p=0.32). Renal impairment was 
the most common contraindication.  
Of the 132 cases, 98 cases (74.2%) reported at least one clinical condition which might 
cause acidosis (some cases had more than one condition, Table 12); acute renal failure (in 56 
patients; n=98, 57.1%) was most common. Ten patients (n=98, 10.2%) had documented cardiac 
failure or circulatory collapse.    
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Of the 152 cases, 78 cases (51.3%) reported metformin as the only medication being 
taken. The most commonly prescribed anti-diabetic medications in addition to metformin were 
sulfonylureas (39.5%, Table 13). Ten medications associated with Type B2 LA were identified 
in 29 cases (n=152, 19.1%; some cases had more than one medication associated with type B2 
LA). Four cases (n=152, 2.6%) reported metformin use with a contrast medium.  
 
Table 12 Patient characteristics (survived vs non-survived) 
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 All patients 
(n=132) 
Survived 
(n=109) 
Non-
survived 
(n=23) 
p  
Age (years) 
 N 132 109 23  
 Mean ± SD 68 ± 10 69 ± 10 69 ± 10 0.89 * 
 Median (IQR) 68 (63-76) 68 (63-75) 71 (63-78)  
Lactate (mmol/L) 
 N 74 61 13  
 Mean ± SD 12.0 ± 6.0 11.2 ± 5.8 15.6 ± 5.9 0.02 
 Median (IQR) 10.3 (7.7- 
16.5) 
10.0 (6.6-
16.2) 
14.6 (10.1-
20.0) 
 
pH 
 N 51 42 9  
 Mean ± SD 7.0 ± 0.2 7.1 ± 0.2 6.9 ± 0.2 0.07 
 Median (IQR) 7.1 (6.9-
7.2) 
7.1 (6.9-
7.2) 
6.8 (6.7-
7.1) 
 
Serum creatinine (µmol/L) 
 N 65 53 12  
 Mean ± SD 535 ± 315 553 ± 319 455 ± 297 0.44 
 Median (IQR)  560 (223-
735) 
560 (230-
730) 
391 (199-
782) 
 
Metformin daily dose (mg) 
 N 118 96 22  
 Mean ± SD 2124 ± 966 2130 ± 932 2098 ± 1126 0.91 
 Median (IQR) 2000 (1500-
3000) 
2000 (1500-
3000) 
2000 (1000-
3000) 
 
Therapy  
 Inotrope/Vasopressor (n; (%)) 25 (18.9) 18 (16.5) 7 (30.4) 0.14 † 
 Renal replacement therapy (n; (%)) 52 (39.4) 43 (39.4) 9 (39.1) 0.98 
 Ventilation/Intubation (n; (%)) 9 (6.8) 8 (7.3) 1 (4.3) 1.00 † 
Medical history 
 Contraindication to use metformin (n; (%)) 35 (26.5) 27 (24.8) 8 (34.8) 0.32 
 Heart failure (n; (%)) 10 (7.6) 9 (8.3) 1 (4.3) 1.00 †  
 Renal impairment (n; (%)) 27 (20.5) 21 (19.3) 6 (26.1) 0.56 †  
 Hepatic dysfunction (n; (%)) 6 (4.5) 2 (1.8) 4 (17.4) <0.01 
†  
 Pancreatitis (n; (%)) 1 (0.8) 1 (0.9) 0 1.00 †  
 Infection (n; (%)) 10 (7.6) 9 (8.3) 1 (4.3) 1.00 † 
 Cancer (n; (%)) 2 (1.5) 1 (0.9) 1 (4.3) 0.32 † 
Adverse effect 
 Patients had at least one of the following 
adverse effect documented (n; (%)) 
98 (74.2) 80 (73.4) 18 (78.3) 0.63 
 Cardiac failure/Circulatory collapse (n; 
(%)) 
10 (7.6) 5 (4.6) 5 (21.7) 0.01 † 
 Hepatic failure/hepatic function abnormal 3 (2.3) 1 (0.9) 2 (8.7) 0.08 † 
 Acute renal failure (n; (%)) 56 (42.4) 45 (41.3) 11 (47.8) 0.56 
 Renal impairment (n; (%)) 7 (5.3) 6 (5.5) 1 (4.3) 1.00 † 
 Dehydration (n; (%)) 8 (6.1) 8 (7.3) 0 0.35 †  
 Respiratory function abnormal ‡ (n; (%)) 7 (5.3) 6 (5.5) 1 (4.3) 1.00 †  
 Anaemia (n; (%)) 3 (2.3) 2 (1.8) 1 (4.3) 0.44 †   
 Cardiac/cardiopulmonary arrest (n; (%)) 3 (2.3) 3 (2.8) 0 1.00 †   
 Seizure (n; (%)) 2 (1.5) 1 (0.9) 1 (4.3) 0.32 †  
 Shock (n; (%)) 6 (4.5) 3 (2.8) 3 (13.0) 0.06 †  
 Sepsis (n; (%)) 6 (4.5) 4 (3.7)  2 (8.7) 0.28 †  
 Diarrhoea/nausea/vomiting (n; (%)) 45 (34.1) 38 (34.9) 7 (30.4) 0.68 
SD: standard deviation. 
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* Age was tested by independent t-test; lactate, plasma pH, creatinine and metformin dosage were 
tested using Mann-Whitney U test; 
† The result from Fisher’s exact test was reported; the others were presented with the result of the 
Pearson chi-square test; 
‡ Respiratory function abnormal: included the description of respiratory impairment, respiratory 
disorder, exacerbation of asthma, respiratory distress, respiratory complication associated with lung 
cancer, respiratory failure. 
 
Table 13 Medications usage in 152 patients 
Medications  Number of patients (%) 
Other anti-diabetic medications  
 One anti-diabetic medication in addition to 
metformin 
63 (41.4) 
 Two anti-diabetic medication in addition to 
metformin 
11 (7.2) 
 Insulin 18 (11.8) 
 Sulfonylureas  60 (39.5) 
 Thiazolidinediones 5 (3.3) 
 DPP-4 inhibitors 1 (0.7) 
 Exenatide  1 (0.7) 
Medications associated with Type B2 lactic acidosis 
 Isoniazid 1 (0.7) 
 Linezolid  2 (1.3) 
 Theophylline  1 (0.7) 
 Valproate  2 (1.3) 
 Spironolactone  8 (5.3) 
β-agonist‡ Salbutamol 15 (9.9) 
 Salmeterol 5 (3.3) 
Anti-retroviral Stavudine  1 (0.7) 
 Didanosine  1 (0.7) 
 Tenofovir 1 (0.7) 
DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors. 
 
 Discussion 
The present study analysed a total of 152 LA cases associated with metformin usage from the 
national pharmacovigilance database in Australia. The mortality in this present study was 
approximately 17%, which was lower than reported rate in the previous literature.189, 196 It is 
possible that the severity of the cases was different (i.e. the plasma lactate levels in this present 
study were typically lower than in previous studies).196-198 For instance, Renda et al.196 recently 
reported a mortality rate of 25.4% of MALA by reviewing the LA cases between 2001 and 
2011 in the National Pharmacovigilance Network of the Italian Medicines Agency, noting a 
mean lactate level of 15.2 mmol/L in all the patients (vs. 12.0 mmol/L in this present study). 
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Kajbaf and Lalau reported the mortality rate associated with MALA fell steadily from around 
50% to 25% since the 1960s, based on a worldwide pharmacovigilance database,113 suggesting 
that it might reflect the change in the outcome of systemic pathologies present in metformin-
treated patients. The worldwide database used in their study included cases from different 
countries, in which adverse event reporting systems might be different; this may explain the 
difference of mortality rate from our estimation. Also, improvements in clinical management 
over the years might have been important in lowering the mortality.199, 200 
The cases of MALA in this present study frequently reported the presence of pre-
existing contraindications and other risk factors of LA, so it might be true that metformin is 
often unfairly implicated as a cause of LA.201 We observed more than one-quarter of patients 
had conditions contraindicating the use of metformin. Similar findings of metformin frequently 
being prescribed, disregarding the contraindications, have been reported.170, 177 The incidence 
of LA in patients receiving metformin with contraindications has apparently not increased.133-
135 For instance, renal impairment may lead to the accumulation of metformin as it is excreted 
through the kidney. However, a recent cohort study of more than 77,000 patients with T2DM 
treated with metformin found that the incidence of LA did not differ from patients with or 
without renal impairment.202 Besides, there was no correlation between the lactate level and 
the serum creatinine in our result.  
Besides the pre-existing chronic medical conditions, most of MALA cases were 
complicated with acute medical conditions, which made it difficult to identify the cause of LA. 
Acute conditions including circulatory collapse, shock and sepsis were reported as AEs in 
approximately 75% of the cases, and these acute conditions are commonly associated with the 
risk of LA.122, 203 More than one-fifth of patients who died were reported to have cardiac failure 
or circulatory collapse. Underlying conditions such as circulatory failure, rather than metformin, 
have been suggested more likely to be the reason of LA.193 Circulatory failure is one of the 
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most common causes of LA.118, 122 Acute kidney failure, found in more than 40% of patients in 
this study, may also contribute to the development of LA. According to the Cohen and Woods 
classification type B1, acute kidney failure is associated with LA.118   
Some medications should also be taken into consideration as a possible contributor in 
developing acidosis; these include valproate and anti-retroviral agents.121, 204 Cases of LA 
associated with medications, such as anti-retroviral agents and salbutamol, have been 
reported.205-207 Approximately 19% of the patients in this study received at least one other 
medication implicated in drug-induced LA according to the Cohen and Woods classification 
type B2.118, 121 Notably, the co-medications that may trigger the occurrence of LA in cases 
associated with metformin were not often documented in previous studies of MALA cases.  
It is often difficult to identify the contribution of metformin in LA cases due to the 
complexity in the acute condition (in presence with other co-existing conditions). Instead of 
“metformin-associated lactic acidosis”, the term “mixed lactic acidosis in metformin-treated 
patients” has been used, suggesting that “mixed” would better reflect the combination of other 
factors.113 Furthermore, it has been suggested that no consistent correlation between metformin 
serum level and LA has been established in previous studies.161, 208 In addition, we also found 
six patients noted with metformin overdose in this database. Metformin overdose (> 3,000 mg 
per day), may cause mitochondrial dysfunction and lactate overproduction.209 Cases of LA in 
metformin overdose have been reported previously.210 with increased peak lactate level in most 
cases.  
Our estimation of the incidence of LA cases associated with metformin in the 
community was 2.3 cases (ranged between 0.5 and 6.8 cases) per 100,000 patient-years, which 
might be an underestimation due to likely under-reporting of cases to the TGA. The published 
incidence of MALA has been estimated by two approaches: spontaneous reports to regulatory 
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agencies and pharmacoepidemiological studies in patients receiving metformin.201 Compared 
to the incidence in pharmacoepidemiology studies, the estimated incidence from spontaneous 
reports is lower, as there is under-reporting due to unrecognised and unreported cases.211 
Initially, the risk of MALA from the Food and Drug Administration following the approval of 
metformin in the US was reported at about 5 cases per 100,000 patient-years.111 It is often 
agreed that the incidence of MALA using spontaneous adverse effect reports could be 
underestimated.201, 212 
When interpreting the findings of this study some limitations should be considered. The 
AE reports did not always have complete documentation in the database (e.g. the outcome was 
unknown in 20 patients.). Although the dosage of metformin was documented in most of the 
cases, the adherence to the treatment was unknown, as was serum metformin concentration. 
Hence, we were not able to establish the potential correlation between metformin level and LA, 
and also not able to conclude that the presence of LA was definitely induced by the use of 
metformin. The estimated patient number receiving metformin was calculated using the annual 
numbers of community prescriptions of metformin divided by twelve, with the assumption of 
each patient having one prescription per month, which may not reflect the real number of 
prescriptions in each patient individually. However, the annual number of prescriptions from 
Australian Statistics on Medicine is the best source to be used in estimating the community use 
of medication since it includes both subsidised and non-subsidised prescriptions. 
 
 Conclusion 
The results showed that the other underlying clinical conditions or medications associated with 
risk of LA were frequently reported in MALA cases, which may also contribute to the severity 
of the illness. Metformin might be unfairly implicated as a cause of LA in cases with multiple 
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conditions. Our estimated incidence of MALA was lower than most of the previously reported 
values, probably because these AE cases were reported spontaneously. While ethically difficult, 
a detailed prospective study in patients with contraindications in association with LA is ideally 
warranted to establish the way in which metformin is to be used in these patients and also have 
a better understanding about the development of LA in metformin-treated patients.  
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Chapter 5 Lactic acidosis and the relationship with metformin usage: case 
reports 
5 Abstract  
Aims: The principal objective of this study was to retrospectively review a series of cases of 
lactic acidosis (LA) in patients with type 2 diabetes mellitus (T2DM) and examine the 
relationship with the use of metformin. More generally, the study enabled an investigation of 
the profiles of patients diagnosed with LA and clinical variables associated with in-hospital 
mortality. 
Methods: All patients admitted to the Royal Hobart Hospital in Tasmania with LA (lactate > 
5.0 mmol/L and pH <7.35) over a four-year period were included. Data extracted included 
patient demographics, medical history, medications, acute and chronic conditions associated 
with LA, and relevant pathology results. Multivariate logistic regression analysis was used to 
identify predictors for in-hospital mortality in patients with LA. 
Results: A total of 139 patients with LA were included in this study. More than half (n=72, 
51.8%) of the patients died during hospitalisation. Multivariate logistic regression revealed 
older age and lower pH as the significant independent predictors (p<0.05) for in-hospital 
mortality in patients with LA. A total of 23 patients had T2DM and 11 patients were taking 
metformin. All metformin-treated patients had at least one additional medical condition (either 
chronic or acute) associated with an increased risk for LA.  
Conclusion: LA was associated with high in-hospital mortality, with older age and lower pH 
as the significant risk factors for mortality. In patients with LA, approximately half of the 
patients with T2DM were receiving metformin. All the patients treated with metformin had 
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other medical conditions which were risk factors for developing LA. The results support the 
“cautious expansion” of metformin use in patients with T2DM. 
 
 Introduction 
Lactic acidosis (LA) is defined as a state of decreased systemic pH (pH <7.35) and an elevated 
plasma lactate concentration (> 5mmol/L).  It remains the most common cause of metabolic 
acidosis in hospitalised patients.213 A recent review summarised the major causes of LA and 
the presumed mechanisms.122 Typically, LA is divided into disorders associated with tissue 
hypoxia (type A) and disorders in which tissue hypoxia is absent (type B). Type A LA may 
result from severe heart failure, sepsis, or cardiopulmonary arrest; type B can be caused by 
renal and hepatic failure, diabetes mellitus (DM) or drugs and toxins, including metformin, 
valproate and anti-retroviral agents.118, 121 It has been reported that cardiogenic or 
hypovolaemic shock, severe heart failure, trauma and sepsis were the most common causes of 
LA.214 
Lactate accumulation may be caused by increased production (i.e. increase glycolysis 
caused by hypoperfusion, hypoxaemia), decreased clearance (impaired hepatic metabolism or 
renal excretion), or a combination of both.114 The exact pathophysiology of elevated lactate is 
likely to be the result of more than one condition. Many studies have shown that high lactate 
levels are associated with increased mortality.122, 203, 215 The mortality rate of LA has been 
reported to be between 50% and 83%.216-218  
DM has been also considered as one of the causes of LA.122 The possible explanations 
include: (i) LA in patients with diabetic ketoacidosis, which is likely to be due to 
hypovolaemia;122 or (ii) reduced activity of pyruvate dehydrogenase, which may cause increase 
lactate levels in patients with DM independent of ketoacidosis.158 In addition, diabetic patients 
79 
 
with micro- or macrovascular disease are at an increased risk of LA, possibly due to the 
associated systemic hypoxia.158 Furthermore, metformin, which is the first choice for the 
pharmacological treatment of type 2 diabetes mellitus (T2DM) in Australia9 and many other 
countries,33, 219 has also been reported to be associated with LA. However, it has been suggested 
that the development of LA in metformin users was most likely due to the presence of 
concomitant risk factors,193 rather than metformin alone. A causal link between metformin and 
LA is yet to be scientifically established.  
Given this background, the principal objective of this study was to retrospectively 
review a series of cases of LA in patients with T2DM and examine the relationship with the 
use of metformin. More generally, the study investigated the profiles of patients diagnosed with 
LA and clinical variables associated with in-hospital mortality.    
 
 Methods  
This retrospective audit included patients with a diagnosis of acidosis and who were admitted 
to the Royal Hobart Hospital (RHH), Tasmania between 1st January 2010 and 31st December 
2013 (A four-year time frame was chosen based on practical reason, due to very low incidence 
of LA in metformin-treated patients and the difficulty in reviewing paper-based 
documentation.). RHH is the principal referral hospital in Tasmania; it has 500 beds serving 
around 250,000 people in southern Tasmania. Patients were included in the study if they were 
admitted for at least an overnight stay, aged 18 years and above, and noted to have acidosis 
(ICD10 E87.2) either at the time of admission or during their hospital stay.  LA cases were 
identified as per documentation in the medical record and from the pathology results (lactate 
level > 5 mmol/L and a pH < 7.35 from the same sample). There were no additional exclusion 
criteria applied in this study.  
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For the purpose of this study, the maximum lactate value in each LA case was 
documented; and the pH value shown in the same test was reported. The LA cases associated 
with the usage of metformin were reviewed separately. 
Other data extracted from patients’ medical records included reason for admission, 
demographics, medical conditions (both chronic and acute), medications, and relevant 
pathology results (e.g. lactate, pH, bicarbonate, estimated glomerular filtration rate (eGFR), 
serum creatinine (SCr), albumin, total bilirubin, alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), and gamma-glutamyl transferase (GGT)).  
For the purpose of this study, liver disease was defined either by documentation in the 
patient’s medical history or by the presence of abnormal liver function tests (LFT), defined as 
hypoalbuminaemia and abnormal serum levels of at least two of the following (greater than the 
upper limit of normal): total bilirubin, ALT, ALP, and GGT. Acute kidney injury (AKI) was 
documented if noted in the patient’s record during hospitalisation, or strongly suspected based 
on at least two increased SCr values.  
All medicines potentially implicated in drug-induced LA were identified according to 
the Cohen and Woods classification type B2, a form of LA caused by drugs or toxins with no 
clinical evidence of insufficient tissue oxygen delivery. The following medicines were 
included: metformin, isoniazid, linezolid, theophylline, valproate, spironolactone, beta-
agonists, and nucleoside reverse transcriptase inhibitors.118, 121 
The data was summarised and analysed using IBM SPSS Statistics for Windows, 
Version 22.0 (IBM Corp., Armonk, NY, US). Descriptive statistics were used to describe the 
data. Chi-square or Fisher’s exact tests were performed for the categorical variables. 
Independent t-tests were performed for comparing the continuous variables. Spearman tests 
were used to explore the possible correlation between age, lactate, pH, bicarbonate and eGFR. 
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Backward logistic regression was used to identify the independent risk factors for in-hospital 
mortality in patients with LA. Variables whose probability (p) values were ≤0.10 in the 
univariate analysis were entered into the final logistic regression model.  A p value of <0.05 
was considered statistically significant. The study was approved by the Tasmania Health and 
Medical Human Research Ethics Committee (Reference number: H0014090).  
 
 Results  
Overall, 476 patients with acidosis during the study period were screened for inclusion. A total 
of 139 patients who met the definition of LA were included in the final analysis. Of 139 patients 
with LA included in this study (  
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Table 14), the mean age (SD) was 62 ± 18 years (range of 50 to 77 years) and 44.6% were 
female. The mean pH (SD) was 7.14 ± 0.15, with a mean (SD) lactate level of 10.1 ± 4.8 
mmol/L. Spearman tests revealed that an increased lactate level was correlated with decreased 
pH (p<0.01, r=-0.43) and decreased bicarbonate (p<0.01, r=-0.58).  
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Table 14 Number of patients with lactic acidosis 
 All (N=139) Survivor  
(N=67) 
Non-
survivor 
(N=72)  
P 
Gender (female; %) 62 (44.6) 27 (40.3) 35 (48.6) 0.41 
Age (mean ± SD; years) 62 ± 18 56 ± 18 68 ± 17 <0.001 
 < 70  83 (59.7) 50 (74.6) 33 (45.8)  
 70-79  30 (21.6) 9 (13.4) 21 (29.2)  
 ≥ 80  26 (18.7) 8 (11.9) 18 (25.0)  
pH (mean ± SD)                                  7.14 ± 0.15 7.18 ± 
0.13 
7.11 ± 0.16 <0.01 
Lactate (mean ± SD; mmol/L)             10.1 ± 4.8 9.6 ± 5.0  10.6 ± 4.6 0.19 
Bicarbonate (mmol/L)  15.1 ± 6.2 16.9 ± 6.1 13.4 ± 5.8 0.001 
eGFR (mean ± SD; ml/min per 1.73m2) 45.3 ± 27.7 55.0 ± 
30.8 
36.0 ± 20.1 <0.001 
Chronic medical conditions  N=131 N=62 N=69  
Patients have at least one chronic 
medical condition (n; %) 
93 (71.0) 39 (62.9) 54 (78.3) 0.083 
 Asthma/COPD  25 (19.1) 12 (19.4) 13 (18.8) 1.00 
 Cancer  21 (16.0) 7 (11.3) 14 (20.3) 0.24 
 CKD  20 (15.3) 8 (12.9) 12 (17.4) 0.64 
 T2DM  23 (17.6) 12 (19.4) 11 (15.9) 0.78 
 Heart failure  15 (11.5) 6 (9.7) 9 (13.0) 0.74 
 Liver disease  52 (39.7) 20 (32.2) 32 (46.4) 0.14 
 Pancreatitis  6 (4.6) 2 (3.2) 4 (5.8) 0.68 * 
 Alcoholism  18 (12.9) 12 (17.9) 6 (8.3) 0.15 
Acute medical conditions  N=139 N=67 N=72  
Patients have at least one acute medical 
condition (n; %) 
118 (84.9) 54 (80.6) 64 (88.9) 0.26 
 Gastrointestinal symptoms  37 (26.6) 19 (28.4) 18 (25.0) 0.80 
 Seizure  11 (7.9) 8 (11.9) 3 (4.2) 0.17 
 Shock  19 (13.7) 5 (7.5) 14 (19.4) 0.07 
 AKI  44 (31.7) 18 (26.9) 26 (36.1) 0.32 
 Acute MI  7 (5.0) 3 (4.5) 4 (5.6) 1.00  * 
 Dehydration  7 (5.0) 4 (6.0) 3 (4.2) 0.71  * 
 Infection  26 (18.7) 10 (14.9) 16 (22.2) 0.38 
 Sepsis  40 (28.8) 13 (19.4) 27 (37.5) 0.03 
Medications implicating type B2 lactic 
acidosis (n; %) 
N=110 N=56 N=54  
Patients have at least one medication 
associated with type B2 lactic acidosis 
(n; %) 
38 (34.5) 24 (42.9) 14 (25.9) 0.10 
 Metformin  11 (7.9) 6 (8.9) 5 (6.9) 0.90 
 Valproate  7 (6.4) 6 (10.7) 1 (1.9) 0.11  * 
 Spironolactone  3 (2.7) 3 (5.4) 0 0.24  * 
 Salbutamol 19 (17.3) 14 (25.0) 5 (9.3) 0.05 
 Salmeterol 9 (8.2) 6 (10.7) 3 (5.6) 0.49  * 
Medications for T2DM (n; %) N=139 N=67 N=72  
 Insulin  6 (4.3) 5 (7.5) 1 (1.4) 0.11  * 
 Sulfonylureas  6 (4.3) 4 (6.0) 2 (2.8) 0.43  * 
 DPP-4 inhibitors  1 (0.7) 1 (1.5) 0 0.48  * 
Treatment (n; %) N=139 N=67 N=72  
 Inotrope/vasopressor  39 (28.1) 14 (20.9) 25 (34.7) 0.10 
 Renal replacement therapy 37 (26.6) 14 (20.9) 24 (33.3) 0.15 
 Ventilation  36 (25.9) 16 (23.9) 20 (27.8) 0.74 
 Intubation  4 (2.9) 3 (4.5) 1 (1.4) 0.56  * 
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* Fisher’s exact test was used. For other categorical parameters, chi-square tests were used to assess 
the association between the parameters and the clinical outcome.  
AKI: acute kidney injury; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; 
DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitors; eGFR: estimated glomerular filtration rate; MI: 
myocardial infarction; LFT: liver function test; T2DM: type 2 diabetes mellitus. 
 
Of the total 139 patients, the most common reasons for admission were: “diseases of 
the circulatory system” (n=36, 25.9%) and “diseases of the digestive system” (n=20, 14.4%). 
There were 131 patients with medical history documented, and the most common chronic 
medical condition associated with LA was liver disease (n=52, 39.7%), followed by 
asthma/chronic obstructive pulmonary disease (n=25, 19.1%). Of the 139 patients, 84.9% 
(n=118) had at least one acute medical condition associated with LA, with the most common 
being AKI (n=44, 31.7%), followed by sepsis (n=40, 28.8%). Of 110 patients with medications 
documented, over 30% of patients with LA were receiving medications (including metformin) 
associated with type B2 LA.  
Of the total 139 patients, more than half (n=72, 51.8%) of the patients who experienced 
LA died during hospitalisation. Compared to survivors, the patients who died were much older 
(p<0.001, Table 1), with over half of them older than 70 years. Univariate analysis to identify 
the risk factors associated with in-hospital mortality showed that age, pH, bicarbonate, eGFR 
and sepsis were all significant (p≤0.10). Multivariate logistic regression revealed two 
significant independent predictors for in-hospital mortality: aging increased the risk of 
mortality by 1.04 times for each additional year (95% CI 1.01-1.06, p=0.003), and a lower pH 
increased the risk of mortality by 25 times with each unit decrease in pH (95% CI 0.002-0.62, 
p=0.02).  
Of the 131 patients with a medical history documented, 23 had T2DM, and 11 of these 
patients died. Approximately half (n=11) of the patients with T2DM were receiving metformin 
(eight patients were receiving metformin monotherapy;   
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Table 14). Of 11 metformin-treated patients, five of them died (45.5%) in the hospital; 
whilst in the non-metformin treated patients, six of them (50%) did not survive. There was no 
significant diffidence in either pH (7.13 ± 0.017 vs. 7.15 ± 0.11, p=0.79) or lactate (10.2 ± 6.9 
vs. 9.3 ± 3.5 mmol/L, p=0.67) between metformin users and non-users, respectively. 
In patients receiving metformin, there were no patients with deliberate overdose, and 
metformin levels were not reported. Of the 11 metformin-treated patients (mean age of 74 ± 13 
years), all patients had at least one medical condition (either chronic or acute) associated with 
an increased risk of LA. However, metformin was documented as the primary reason for the 
development of LA in four patients (patients 2, 5, 7 and 9 in Table 15). In all the other patients, 
sepsis was documented as the most common reason for LA. Five of the 11 patients died either 
at admission or during hospitalisation, with four of these aged 75 years or older. Among the 
patients who survived only one patient had a lactate level > 10 mmol/L (11.3 mmol/L). 
Metformin was re-introduced to all the survivors at discharge.  
  
86 
 
Table 15 Individual information of metformin users with lactic acidosis 
Patient  Gender 
(M/F) 
Age 
(years) 
Days of 
hospitalisation 
(days) 
Death Dose of 
metformin 
(mg/day) 
Glucose 
(mmol/L) 
pH Bicarbonate 
(mmol/L) 
Lactate 
(mmol/L) 
Serum 
creatinine 
(µmol/L) 
eGFR 
(ml/min 
per 
1.73m2) 
1 M 74 60 No 1000 12.1 7.20 13 11.3 108 58 
2 M 75 2 Yes 2000 14.2 6.92 2 29.0 538 8 
3 M 42 22 Yes N/A 8.0 7.06 14 5.2 183 38 
4 M 79 4 Yes N/A 11.0 7.06 12 12.8 86 74 
5 F 81 6 No 1000 10.8 7.31 12 5.6 146 40 
6 M 64 122 No N/A 24.0 6.86 18 8.5 187 32 
7 F 80 29 No 1000 11.6 7.19 11 6.1 148 29 
8 M 84 31 No 1500 11.2 7.34 12 5.1 105 56 
9 M 69 18 No 500 11.0 7.34 23 6.1 160 37 
10 F 92 2 Yes N/A  43.0 7.00 8 12.9 281 12 
11 M 79 2 Yes N/A  10.4 7.23 15 10.0 117 51 
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Continue of Table 15 
Patient  Acute condition Chronic condition (besides 
Type 2 DM) 
Medications 
for T2DM 
Other medication 
associated with type 
B2 lactic acidosis 
Treatment for 
the acute illness 
Reason of death 
1 LFT abnormal  Alcoholic; colorectal cancer Gliclazide  N/A Inotrope, dialysis N/A 
2 AKI; GI symptoms; multi-
organ failure 
Metastatic bowel cancer  
 
N/A N/A Inotrope  Ischemic small 
bowel; Multi-
organ failure 
3 GI symptoms; multi-organ 
failure; respiratory arrest; 
sepsis 
CKD 
 
N/A N/A Inotrope, dialysis  Sepsis caused 
multi-organ failure 
4 GI symptoms; sepsis Hypertension N/A N/A Inotrope, dialysis Ruptured 
abdominal aortic 
aneurysm 
5 Septic shock Hypertension; GORD; 
cataracts 
N/A N/A N/A N/A 
6 Cardiac arrest; LFT 
abnormal 
CKD; gout; hypertension, 
squamous cell carcinoma 
Insulin  N/A Inotrope N/A 
7 Acute MI; dehydration CKD; depression; lupus N/A N/A Ventilation  N/A 
8 GI symptoms; sepsis GORD; prostatic cancer Glimepiride; 
sitagliptin 
N/A Vasopressor  N/A 
9 Dehydration; hypotension; 
respiratory failure; right 
lower lobe pneumonia; 
sepsis 
COPD; osteoarthritis N/A Salbutamol; 
Salmeterol 
N/A N/A 
10 Acute MI; AKI; hypotension; 
HONK 
Ischemic heart disease N/A N/A Inotrope, 
intubation and 
ventilation 
Acute MI 
11 GI symptoms; haematuria Depression; gout; 
hypertension; ischemic heart 
disease; squamous cell 
carcinoma 
N/A N/A N/A Sepsis secondary 
to aspiration 
pneumonia 
AKI: acute kidney injury; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; GI: 
gastrointestinal; GORD: gastro-oesophageal reflux disease; HF: heart failure; HONK: hyperosmolar non-ketotic acidosis; LFT: liver function test; MI: 
myocardial infarction; N/A: not available; SD: standard deviation; T2DM: type 2 diabetes mellitus. 
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 Discussion  
This study was designed to investigate the association between in-hospital mortality and 
multiple clinical factors in patients diagnosed with LA. LA was shown to result from various 
medical conditions, predisposing factors and medications. Despite appropriate management, 
the in-hospital mortality was high (approximately 50%). The most significant risk factors for 
in-hospital mortality were older age and lower pH.  
The in-hospital mortality due to LA of 52% was within the range previously reported. 
The study by Scale and Harvey reported an in-hospital mortality rate of 54%, with an inclusion 
of a pH ≤ 7.2, which was lower than that used in our study (pH < 7.35).158 Also, consistent with 
their findings, this present study found no significant difference in lactate levels between 
patients who died and survived. In both the studies, most cases of LA resulting in-hospital 
mortality were complicated by other medical conditions, such as sepsis and AKI. AKI was 
reported in more than 30% of the cases, and was the most common acute condition associated 
with LA in our study. In our study, compared to survivors, the patients who died had a higher 
rate of sepsis (p=0.03), which has been identified as a common clinical condition associated 
with increased mortality in LA patients.203 Previous studies have demonstrated that mortality 
of LA cases is increased in patients with multiple comorbidities.122, 215 
A total of 23 patients with LA in our study were diabetic. DM, as well as metformin, is 
considered to be one of the causes of type B LA, but to date the exact mechanism of LA has 
not been elucidated. A study reported similar rates of LA in T2DM patients with and without 
metformin, and the authors suggested that LA in metformin users was likely related to the 
underlying medical conditions rather than the use of metformin alone.110 Furthermore, 
sulfonylureas have been suspected of LA with the incidence of LA approximately 4.8 cases per 
100,000 person-years compared to 3.3 cases per 100,000 person-years among users of 
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metformin.26 However, the incidence of LA in T2DM patients receiving other anti-diabetic 
medications is not yet well established. 
In our study, 11 patients were receiving metformin either as monotherapy or in 
combination with other anti-diabetic medications. Five patients treated with metformin 
(45.5%) died, which was higher compared to a previous study conducted in Australia.220 That 
study retrospectively evaluated metformin-associated LA (MALA) cases in an intensive care 
unit over a five-year period, including patients with lactate levels > 2.0 mmol/L and pH < 7.30. 
A total of 17 patients were diagnosed of MALA with an overall mortality rate of 29% (N=5). 
The severity of LA in our study may be different compared to that study, as we only included 
cases with a lactate level > 5.0 mmol/L. Furthermore, our patients receiving metformin were 
older (74 ± 13 years) compared to the study conducted in Adelaide (65 ± 10 years). Previous 
studies have reported that older age is associated with higher mortality in cases of MALA.158, 
221  
The safe use of metformin in patients with other chronic risk factors for developing LA 
is still under debate, especially in patients with CKD stage 3-5 (eGFR < 60 ml/min per 1.73m2, 
including patients on dialysis). Several studies have recently reported that metformin is a 
relatively safe option, including in patients with contraindications to its use, such as kidney 
disease.170, 177 Available data supports the “cautious expansion” of metformin use in T2DM 
patients with mild to moderate renal impairment.222, 223 However, a more careful approach is to 
be considered in patients who are at risk of abrupt worsening of renal function, especially in 
patients with CKD stage 3-4 (eGFR 15-59 ml/min per 1.73m2) , who may have serious clinical 
conditions predisposing to AKI.224 
Furthermore, it is important to note that to date, no consistent link between LA and the 
use of metformin has been found.107, 158, 196, 220, 225 We were not able to identify the contribution 
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of metformin due to the other complications associated with LA in each case; besides, the 
metformin concentration was not measured in the hospital. Instead of “metformin-associated 
lactic acidosis”, a term “mixed lactic acidosis in metformin-treated patients” has been used.113 
This may be more appropriate to describe the LA cases in metformin users (without metformin 
concentration measurement) who have other risk factors associated of LA. 
This study has some limitations. The retrospective study design has resulted in missing 
or incomplete data. A cross sectional study design was used due to the very low annual 
incidence of LA cases in metformin-treated patients. Besides, it is difficult to match the LA 
cases and design a control group, as LA is an acute illness complicated by multiple medical 
conditions. The power of the study is low due to the small sample size. As the inconsistent 
documentation of cause of death in the hospital, and the association with multiple conditions 
of mortality in some patients, it was not always possible to summarise and report the reason 
for in-hospital mortality. We could not conduct any further investigation in the fatal cases to 
confirm the relationship with metformin use. Of 11 patients treated with metformin, the 
dosages were not documented in five patients.  
 
 Conclusion  
LA was associated with high in-hospital mortality, with older age and lower pH as the 
significant risk factors for mortality. In patients with T2DM, approximately half of the patients 
were receiving metformin, and the mortality was similar between metformin users and non-
users. All metformin-treated patients had other underlying medical conditions associated with 
the developing LA. The results support the “cautious expansion” of metformin use in patients 
with T2DM. 
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Chapter 6 Lactate levels in chronic metformin users: a narrative review 
6 Abstract  
Lactic acidosis (LA) cases had been reported in patients treated with metformin in two studies 
containing in Chapter 2 and 4; however, all the cases of metformin-associated lactic acidosis 
(MALA) reported in these two chapters were associated with other con-existing factors (i.e. 
acute illness, contraindications to the use of metformin). It was very difficult to identify the 
contribution of metformin in developing LA. Recently, more evidence from elsewhere 
suggested that metformin is generally safe to be used chronically in most patients. But it 
remains unclear whether metformin increases lactate levels chronically, as lactate level is not 
commonly measured in practice. The aim of this review was to summerise existing literature 
on the changes of lactate levels in chronic metformin users. The studies were subdivided into 
four themes summarising the lactate levels in metformin-treated patients, who (i) did not have 
contraindication to its use; (ii) had contraindication(s), especially in those have renal 
impairment; (iii) did physical exercise, which itself can raise lactate levels, at least acutely; 
(iv) received concomitant treatment with a nucleoside reverse transcriptase inhibitor (also 
known to have the ability to increase lactate levels).  
 
 Introduction  
The potential risk of developing lactic acidosis (LA) is a major concern that has hindered the 
prescribing of metformin,222, 226 although metformin is one of the most widely used medications 
in the treatment of type 2 diabetes mellitus (T2DM) in practice. According to the official 
product information of metformin,84, 148 it is contraindicated in conditions including those with 
the potential to cause tissue hypoxia (i.e. cardiac failure, respiratory failure, sepsis) and those 
with the potential to alter renal function (i.e. dehydration, severe infection). As metformin is 
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mainly excreted through the kidneys unchanged, the official product information of 
manufacturer recommends avoiding use in patients with renal impairment (creatinine clearance 
(CrCl) < 60 ml/min).84 However, other sources, such as the Australian Medicines Handbook 
(AMH),100 recommends avoiding metformin in patients with CrCl of less than 30 ml/min. It is 
important to note that the kidney also contributes to lactate metabolism and clearance, to the 
extent of 10-20%.115  In conditions where there is damage to the kidney, the elevation of lactate 
levels increases the risk of lactic acidosis. However, these warnings in the product information 
have been found to be increasingly disregarded in practice.153, 170, 177 Recently, metformin was 
reported as one of the most frequent prescribed anti-diabetic drug despite the presence of 
contraindications to it use.227 The occurrence of LA in metformin users is rare,26, 137 which has 
led to the debate that metformin is generally safe to use despite contraindications.133 
Studies have proposed several possible intracellular pathways likely to be involved in 
metformin increasing lactate production;55, 59 however, the exact mechanism is still not known. 
So far, it is not clear whether metformin increases lactate levels gradually throughout the 
treatment (non-acute condition), or whether the sudden rise in lactate level is triggered by a co-
existing acute illness (acute condition).  
Lactate level is not commonly being tested in clinical practice. In patients receiving 
metformin, lactate levels were mainly documented in individual or series of case reports of 
“metformin-associated lactic acidosis (MALA)”, an acute illness mostly occurring in the 
presence of other complications.196 It was hard to identify if metformin was responsible for LA 
through these acute cases, as the complications may also be independently associated with the 
risk of developing LA. Limited studies published have reported lactate levels with continued 
metformin usage; therefore, it is not clear to what extent metformin would increase the lactate 
production with chronic regular use.  
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It is recommended that physical exercise and physical training would be beneficial in 
patients with T2DM.228 However, it has been suggested that lactate in patients with T2DM 
might not be metabolised so quickly compared to that in healthy subjects.229 Also, physical 
exercise can shortly and rapidly increase the lactate level,230, 231 which may particularly elevate 
the lactate levels in metformin-treated users. However, it is not clear to what extent lactate 
levels are affected in metformin users when they do exercise.  
Nucleoside reverse transcriptase inhibitors (NRTIs), commonly used in treating 
patients with a diagnosis of human immunodeficiency virus (HIV), also have a side effect of 
developing LA.122 A systematic review identified that NRTI was one of the risk factors (the 
other one was female gender) for the development of LA in HIV infected patients.232 
Metformin has been introduced to patients who have had a diagnosis of human 
immunodeficiency virus (HIV), for its effect on improving insulin resistance and potential 
cardiovascular benefits.233, 234 Both agents are implicated with type B2 LA according to the 
Cohen and Woods classification.118, 121 232However, in practice, the changes in lactate levels in 
patients receiving both metformin and a NRTI are not clear.  
Although metformin is commonly prescribed for patients with diabetes, it remains unclear 
whether the lactate level increases in chronic metformin users, and to what extent. This review 
examines lactate levels in chronic metformin-treated patients, including studies with the 
following conditions: 
 Patients without contraindications to the use of metformin;  
 Patients with contraindication(s) to the use of metformin, especially patients with renal 
impairment; 
 Patients doing exercise;  
 Patients who are HIV-positive and receiving NRTI therapy. 
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Whether monitoring lactate routinely would be useful is dependent on the findings of this 
review. 
 
 Methods 
We searched the PubMed, Embase, Web of Science, Cochrane and International 
Pharmaceutical Abstracts databases covering the period up to 31 December 2015. Search terms 
included combinations of terms and key words, including “metformin”, “lactate”, “lactic acid” 
and “lactic acidosis”. Articles written in English were retrieved.  The studies with an aim of 
reporting lactate levels in patients receiving metformin were included. Cases series of LA or 
MALA were excluded (blood/plasma sample: lactate > 5mmol/L and pH <7.35). Studies that 
included at least 10 patients taking metformin were included. 
Titles and abstracts of the articles were screened to include relevant studies. In cases of 
insufficient information being ascertained from the title or abstract of a paper, a full copy of 
the article was obtained and screened to determine eligibility. Each article was evaluated for 
inclusion by the candidate (WH). 
 
 Results  
A flow diagram of the literature search and identification of relevant articles for review is 
depicted in  
Figure 5 
Figure 5. Overall, 1,291 potentially relevant articles were identified. A total of 45 articles 
reported lactate levels in metformin users. The studies were subdivided into four themes as 
follows:  
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 Lactate levels and metformin usage in patients without contraindications;  
 Lactate levels and metformin usage in patients with contraindication(s), or with renal 
impairment but without other contraindications;  
 Lactate levels in patients taking metformin who exercise; 
 Lactate levels in patients taking metformin who are HIV positive and receiving NRTI 
therapy. 
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Figure 5 Flowchart of study selection for this review 
 
#1 
 Not relevant n=144 
 reviews n=315 
 Single case reports / Cases series <10 patients n=256 
 Letter /Commentary n=95 
 Animal / In vitro n=127 
#2 
 Lactate level not available n=120 
 PK study n=15 
 Subject matter not applicable n=68 
 Case series of lactic acidosis or metformin-associate lactic 
acidosis n=55 
Articles assessed for 
eligibility N=303 
 
Records identified in 
databases N=2323 
 
PubMed n=627 
Embase n=877  
Web of Science n=677 
IPA n=112 
Cochrance n=30 
 
Records after duplicates 
removed N=1291 
 
Articles included N=45 
 
#1 records excluded N=988 
 
#2 articles excluded N=258 
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 Lactate levels and metformin usage in patients without contraindications 
Table 16 summarises the lactate level changes in the studies which excluded patients with any 
contraindications to the use of metformin or any comorbid conditions of diabetes. Most of these 
studies were conducted prospectively, and the lactate levels in metformin users were presented 
in comparison to the baseline level (before initiating metformin) or to the levels of non-
metformin users (either receiving placebo or other diabetic medications).  There were no cases 
of LA reported in any of these studies.  
In the studies comparing lactate levels before and after the initiation of metformin 
therapy, most of the results showed slightly increased lactate levels in patients after the drug 
treatment, but the results were not statistically significant (Table 16). An early study published 
in 1996 reported slightly increased lactate levels in postprandial measurements (p<0.05), after 
adding metformin (1,000 mg per day) to sulfonylurea therapy in 76 elderly patients, but not in 
the fasting state.235 Another study also reported lactate levels increased in patients after 
receiving metformin. That study was designed as a double-blind, cross-over clinical trial, 
testing two formulations containing different glibenclamide dosages in combination with 
metformin (800 mg per day initially, increased to 1,200 mg per day) in a total of 197 patients.236 
The lactate levels in both groups with different medication sequences increased significantly 
compared to their baseline levels, but no clinically significant abnormalities were observed in 
either group.  
Few studies have compared the lactate levels between metformin users and non-users. 
A study reported that postprandial lactate levels increased significantly in patients with T2DM 
and obesity, but the basal plasma lactate levels were not affected by metformin treatment.237 
The authors considered the changes in lactate level were within the normal range and much 
less compared to the effects of exercise. The majority of studies monitoring lactate levels in 
metformin users without contraindications were conducted in the 1990s or even earlier. Most 
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of these studies were designed to investigate the therapeutic outcome and safety profile of 
metformin, and the results suggested that lactate levels remained the same after initiation of 
metformin treatment235, 238-243 or in comparison to non-metformin users.237, 244, 245  
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Table 16 Studies without including patients with contraindications to metformin treatment 
Reference: 
First author, 
year 
Number of 
patients 
receiving 
metformin  
Follow 
up  
Lactate level of metformin users  Chronic medical conditions  
Compare to 
baseline 
Compare to 
placebo/other 
diabetic treatment 
He 2012246 180 24 
weeks 
 No difference  
(p=0.074) 
Main exclusion criteria included: diabetes; known allergy or 
hypersensitivity to trial drugs; New York Heart Association grade II–
IV heart failure, myocardial infarction or cerebrovascular accident in 
one year preceding the trial; acute infections; tumour; severe 
arrhythmia, mental disease, drug or alcohol abuse; history of 
hepatitis or cirrhosis or severe kidney disease; pregnant or 
lactating; or enrolled in other trials within the past 3 months. 
Baradari 
2011244 
94 60 
hours 
 No difference 
(p=0.793) 
Patients were excluded due to liver disease, renal disease, heart 
failure, history of contrast or angiography within two days of 
surgery. 
Iannello 
2004238 
20 10 
days 
No change*   Patients recruited comprised subjects with obesity or overweight or 
very mild diabetes, most often undiagnosed, who were observed in 
ambulatory or day-hospital for metabolic evaluation and dietary 
treatment.  
None of the subjects was taking medications of any kind nor had 
diabetic complications (ocular or renal) or other diseases. 
Brunetti 
2004236 
197 6 
months 
Increase†  Patients were excluded due to severe diabetic complications (e.g. 
ketoacidosis, hyperosmolarity, severe infections); respiratory, 
cardiovascular (HYHA class III-IV), hepatic, or renal diseases, or 
pregnant, lactating or potentially child-bearing females. 
Gregorio 
1999247 
89 18 
months 
Increase (fasting 
and average 
overall)* 
 Patients were excluded due to the contraindication to increasing 
sulphonylureas dose or adding metformin: alterations in liver 
function, severe macroangiopathy, respiratory or congestive heart 
failure, reduced renal function and excessive alcohol consumption.    
Gregorio 
1996235 
76 12 
months 
No change  
(fasting)*  
Increase  
(postprandial)† 
 All patents had normal renal function and liver function test results; 
no severe macro-angiopathy or respiratory or congestive heart 
failure. 
DeFronzo 
199546 
356 29 
weeks 
Increase* Increase* Patients were excluded if they had any of the following: 
symptomatic diabetes (polyuria, polydipsia, and weight loss), 
symptomatic cardiovascular disease, diastolic blood pressure 
above 100 mm Hg during antihypertensive-drug treatment, or any 
concurrent medical illness. 
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Patients were also excluded if they had received insulin therapy 
within the previous six months, used medications known to affect 
glucose metabolism, consumed three or more alcoholic drinks per 
day (≥ 3 oz of alcohol per day), used illicit drugs, or had previously 
received metformin therapy. 
Stumvoll 
1995239 
10 16 
weeks 
No change  
(fasting)* 
 Healthy obese patients with type 2 diabetes mellitus. 
Campbell 
1994240 
24 
 
52 
weeks 
No change  
(fasting)* 
 All patients were non ketotic, no evidence of cardiac failure, and 
with normal urea and electrolytes, creatinine and liver function 
tests. No alcoholic. None were taking steroids, salicylates, warfarin 
or monoamine oxidase inhibitors. 
Yoa 1993248 10 4 
weeks 
Decrease (red 
blood cell)‡ 
 10 Patients were healthy volunteers and the other 10 were newly 
diagnosed with type 2 diabetes mellitus. 
DeFronzo 
1991249 
14 3 
months 
Increase *  Patients were diagnosed with type 2 diabetes mellitus: six with 
normal weight and 8 with obesity, but no major complication.  
Pentikainen 
1990241 
23 
 
3 
months 
No change*   Patients were excluded due to renal or hepatic disease, heart 
failure, diabetes, body mass index > 40, pregnancy, use of drugs 
known to affect lipid levels, poor co-operation, and a high 
consumption of alcohol. 
Gregorio 
1990242 
20 5 
weeks 
No change*  Patients had normal hepatic and renal functions and no evidence of 
vascular complications except for one patient with signs of initial 
and mild retinal microangiopathy. 
Josephkutty 
1990250 
20 12 
weeks 
Increase*   Patients were excluded due to abnormal blood urea, creatinine or 
liver function test and had a recent episode of cardiac failure. 
Pedersen 
1989237 
10 4 
weeks 
 No difference  
(fasting)* 
Increase 
(postprandial)† 
The patients were obesity. 
None of the patients suffered from vascular complications or 
presented with biochemical evidence of abnormal hepatic or renal 
function. 
Campbell 
1987245 
14 24 
weeks 
 No difference  
(fasting)* 
All patients were non-ketotic with had normal serum urea, 
electrolytes, and creatinine. None alcoholic or abnormal liver 
function test. 
Marchetti 
1987251 
13   Increase† 
compared to 
normal individuals 
Patients had normal liver and renal function. The other medical 
conditions were not specified. 
Pagano 
1983243 
14 4-6 
weeks 
No change*  Patients had normal liver and renal function. The other medical 
conditions were not specified.  
De Silva 
1979252 
19  6 
months 
 Increase† 
compared to 
None of the subjects was taking any drugs and there was no 
evidence of hepatic or renal dysfunction or other endocrine 
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*result was not changed significantly; †p<0.05; ‡no p value reported.
treatment of 
clofibrate  
disease. 
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 Lactate levels and metformin usage in patients with contraindications 
Metformin has been widely used in the presence of contraindications to its use.253, 254 In the 
studies included in this review, the reported changes in lactate levels were not consistent (Table 
17).  
A prospective cohort study reported increased mean lactate levels in 110 metformin 
users (as monotherapy or in combination with sulfonylureas or insulin);255 approximately 57% 
of the participants had elevated lactate levels after a follow-up period of two years. The patients 
included may have had other comorbidities, but they all had normal renal function. The mean 
lactate level in the high lactic acid group was 2.21 ± 0.57 mmol/L, with a range from 1.44 to 
5.66 mmol/L; the detailed information of the cases with lactate higher than 5 mmol/L were not 
reported individually. The authors suggested that the duration of treatment with metformin 
(ranged from three to 36 months) did not seem to influence the plasma lactate levels. At the 
final evaluation of the study, high lactate levels were found in some of the patients, who were 
grouped separately from those with normal lactate. Compared to those with normal lactate, 
patients with high lactate levels had a higher ratio of complications, including congestive heart 
failure and infection. With the investigation of symptoms associated with high lactate levels 
and concurrent morbidities, the authors recommended metformin should be avoided in patients 
who had certain comorbidities (known to cause hypoxaemia or reduce tissue perfusion), 
particularly cardiovascular, respiratory or septic conditions that may enhance lactate 
production, and suggested that normal renal function did not protect patients from metformin-
associated lactic acidaemia.  
The authors of another prospective observational study has also suggested that 
metformin should be used with caution in patients with contraindications or stopped if there 
was evidence of acidosis.256 They considered lactate alone was insufficient to monitor 
effectively for the risk of LA in patients, whether they were metformin-treated or not. Their 
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results showed that metformin was associated with a small but significant increase in fasting 
plasma lactate levels in patients with T2DM compared to those treated with other medications 
(geometric mean [SD range]: 1.86 [1.34-2.59] mmol/L vs. 1.58 [1.09-2.30] mmol/L); both 
hyperglycaemia and being overweight were found to be associated with elevated plasma lactate 
levels. However, the patients treated with metformin had significantly longer durations of 
T2DM, greater BMI, higher pulse rate, fasting glucose, and haemoglobin A1c (HbA1c).  
Different observations of lactate levels in metformin-treated patients were reported in 
other studies. A study reported lactate levels did not differ between the elderly (aged ≥ 80 
years) and control groups (aged < 80 years) (approximately 1.46 ± 0.58 mmol/L and 1.50 ± 
0.53 mmol/L, respectively).257 Patients with fasting plasma glucose levels > 7.2 mmol/L had a 
2.8-fold increased risk of developing hyperlactaemia, but the authors stated that none of the 
cases fulfilled the LA criteria. Besides, the results showed that patients in the elderly group had 
a significantly lower daily metformin dose, higher creatinine levels, and lower estimated CrCl, 
compared with the control group (all p<0.05). The increased lactate level was associated with 
decreased estimated CrCl in the elderly group (p<0.05, r=−0.27), but not in the control group.  
Besides, although increasing number of literature reports suggested metformin seemed 
generally safe to use in patients with T2DM, even in those with contraindication(s), whether to 
stop or continue metformin treatment in patients with contraindications is still under debate. A 
study recruited 393 metformin-treated patients, who were randomised to continue or to stop 
the drug.258 All the patients included had at least one contraindication to the use of metformin, 
with no differences in any of the baseline parameters between the two groups. After a follow-
up of four years, the lactate levels were still similar in both groups (metformin continued vs. 
stopped). Besides, there was no difference between the two groups in the incidence of 
myocardial infarction, all cardiovascular events, or cardiovascular mortality. However, patients 
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who discontinued metformin had significant increase in weight (p<0.002) and HbA1c (p<0.01) 
compared to those who continued the drug. The mean serum creatinine (SCr) also rose 
gradually in both groups (p<0.01, initial vs. final values), but there were no significant 
differences between the groups. The authors suggested that patients with coronary heart 
disease, congestive heart failure and chronic obstructive pulmonary disease (COPD) had no 
reason to discontinue metformin treatment.  
A recent retrospective study259 explored the safety of metformin in patients with T2DM 
who were admitted to the hospital with COPD exacerbation. The authors suggested that COPD 
should not present a barrier to the investigational or clinical use of metformin. The patients 
included in their study were at high risk of lactate accumulation: approximately three-quarters 
were hypoxaemic, over a third were in respiratory failure, and about a quarter had respiratory 
acidosis. Although the median lactate level was higher in metformin-treated patients compared 
to non-metformin treated patients, it remained in the normal range. In addition, they found that 
metformin treatment was associated with longer survival time in this population (5.2 years vs. 
1.9 years, p=0.011), although further evidence is required to support these findings.  
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Table 17 Studies including patients with contraindications (in normal renal function). 
Reference: 
First 
author, 
year 
Number of 
patients 
(metformin 
users/total) 
Follow up  Lactate (mmol/L) Cases 
with 
lactate > 
5 mmol/l 
and pH < 
7.35 
Study population  Chronic medical 
conditions 
(including 
comorbidities of 
diabetes mellitus) 
Metformin group Comparison 
group 
P 
value  
Duong 
2015260 
170 No  Indigenous: 1.55 
(1.20-1.88);  
non-indigenous: 
1.60 (1.35-2.10) 
NA NA No  Patient with T2DM 
receiving metformin 
Not specified 
Hitching 
2014259 
51/130 For survival 1.45 (1.10-2.05)  1.10 (0.80-
1.50)  
0.012 No  Patients with COPD 
exacerbation with 
T2DM 
Not specified 
Morgana-
Chaffin 
2012261 
164/493 No 
(receiving 
medications 4-
week prior 
enrolment)  
1.00 (0.94-1.06)  0.93 (0.88-
0.97)  
<0.05 No  
 
 
Patients with risk of 
atherosclerosis 
involved in 
Communities Carotid 
MRI study 
Not specified 
Lin 2010257 145  
(aged ≥ 80 
years, n=66 
vs. < 80 years, 
n=79 ) 
No  1.46 ± 0.58  1.50 ± 0.53  0.888 No  
 
Patients with T2DM 
receiving metformin  
No specified 
Rachmani 
2002258 
195 
(metformin 
continued) 
/393 (in total) 
4 years Initial 1.50  Initial 1.50  NA No  Patient with T2DM 
receiving metformin 
and with the presence 
of at least one 
contraindication to 
metformin  
Not specified 
Final 1.63  Final 1.66  NA 
Davis 
2001256 
181/272 1 year 1.86 (1.34-2.59)  1.58 (1.09-
2.30)  
<0.001 No  Patients involved in 
Fremantle Diabetes 
study 
Not specified 
Abbasi 
2000255 
110 2 years Final assessment: 
Normal lactate 
group: 1.05 ± 
0.19;  
NA NA No  Patients with T2DM 
receiving metformin  
Normal serum 
creatinine (<132 
µmol/L in men and 
Not specified 
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high lactate 
group: 2.21± 0.57 
(p<0.001) 
<124 µmol/L in 
women) 
Chalmer 
1992262 
70 No Aged ≤ 65 years 
vs. aged > 65 
years: 1.66 ±  
0.58 vs. 1.53 ± 
0.49 (p not 
available) 
NA NA No Patients with T2DM 
receiving metformin 
monotherapy or in 
combination with a 
sulfonylureas 
Not specified 
Waters 
1978263 
40/153 No  1.60 (0.2-4.2)  Sulfonylurea 
1.16 (0.2-3.0) 
<0.05 No  Patients with T2DM 
receiving metformin, 
phenformin or 
sulfonylureas; also 
patients on diet only.  
Not specified  
COPD: Chronic obstructive pulmonary disease; MRI: Magnetic resonance imaging; T2DM: type 2 diabetes mellitus. 
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 Lactate levels and metformin usage in patients with renal impairment but 
without other contraindications  
LA induced by metformin was very rare in patients with normal kidney function.106, 134, 258 The 
reduced renal function may lead to accumulation of metformin,74, 264 which would possibly 
leave patients at a higher risk of developing LA. In practice, there is no clear evidence to 
support whether to start or to continue metformin in patients with a CrCl between 30-60 
ml/min. Some studies have reported measurement of lactate levels in patients with renal 
impairment without other comorbidities of DM or contraindication to metformin use (Table 
18) 
Studies reported that the mean fasting lactate levels showed no significant difference in 
different glomerular filtration rate (GFR) groups.265, 266 A study265 reported the mean fasting 
lactate levels in patients with T2DM treated with metformin in accordance to different renal 
function groups. The patients included were divided into three groups according to their GFR: 
< 60, 60-90, and > 90 ml/min per 1.73 m2 (Table 18). The results showed no increase in fasting 
lactate levels in patients with GFR < 60 ml/min per 1.73m2, and no significant difference in 
fasting plasma lactate of different metformin daily dosages. Results from another study,267 
which included 24 elderly patients (70-88 years) with T2DM,  showed that the mean lactate 
level remained unchanged in patients with CrCl > 60 ml/min receiving  1,700 mg of metformin 
daily over the two months of observation. Interestingly, for those patients with CrCl 30-60 
ml/min, a lower dosage (850 mg per day) was given with a result of reduced mean lactate 
concentration compared to that of the baseline. In addition, there was no correlation between 
metformin levels and CrCl or between metformin levels and lactate levels reported in this 
study.  
However, another two studies elsewhere reported positive correlations between fasting 
lactate level and SCr. The two studies, which did not include patients with renal impairment, 
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showed that the GFR in some of the patients were lower than 60 ml/min per 1.73m2 despite a 
SCr within the normal range.268, 269 In both studies, all the patients were treated with metformin 
1,500 mg daily for at least one week, and the reported mean lactate levels in metformin users 
were significantly higher than those of non-users; however, the lactate levels were still within 
the normal range.  
A study270 evaluated the risk of LA and hypoglycaemia in 35 patients with end-stage 
kidney disease (ESKD) and T2DM who were receiving automated peritoneal dialysis therapy. 
They initiated metformin treatment in patients without other risk factors of LA. Although 85% 
of their patients had a moderate or markedly raised metformin concentration, the mean lactate 
level was 1.39±0.61 mmol/L, and hyperlactatemia (> 2 mmol/L to 5 mmol/L) was found in 
only 4/525 plasma samples, but no patients had a plasma lactate level above 5 mmol/L. Besides, 
no correlation was established from the results between the levels of plasma metformin and 
lactate. The authors suggested the increased lactate was not necessarily a result of metformin 
accumulation.   
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Table 18 Studies including patients with renal impairment 
Reference: 
First author, year 
Num. of 
patients  
Renal function  Lactate in metformin users 
(mmol/L) 
Case of 
hyperlactaemia/ 
lactic acidosis 
Comment  
In different stage 
of renal function 
Mean  
Al-Hwiesh, 2013270 35 End-stage renal disease   1.39 ± 0.61 4/525 blood sample 
with lactate > 2 
mmol/L (but <5 
mmol/L) 
Excluded patients 
with additional risk 
for lactic acidosis 
Shen, 2013268 392 Slightly impaired renal 
function 
 1.26 ± 0.43  Excluded all 
patients with 
additional risk for 
lactic acidosis 
Liu, 2009269 1,024 GFR (ml/min 
per1.73m2) 
<60 1.13 ± 0.47 1.32 ± 0.52 62/1024 patients with 
lactate > 2mmol/L 
Excluded patients 
with additional risk 
for lactic acidosis 
61-90 1.23 ± 0.50 
≥91 1.21 ± 0.49 
Lim, 2007265 97 GFR (ml/min 
per1.73m2) 
<60 1.7 ± 0.3  20 patients with 
lactate >2.2mmol/L; 
1 patients with lactate 
>5.0 mmol/L, but not 
satisfy the criteria of 
lactic acidosis 
Excluded patients 
with additional risk 
for lactic acidosis 
60-90 1.8 ± 0.3 
>90 1.8 ± 0.4 
Connolly, 1996266 42 SCr (µmol/L) >120 2.3 ± 0.8  No  Excluded patients 
with additional risk 
for lactic acidosis 
<120 2.64 ± 1.4 
Lalau, 1990267 24 CrCl (ml/min) 
after 2 months 
>60 1.48 ± 0.18  No  Patients were free 
from 
cardiovascular 
complications and 
had normal 
hepatic function. 
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 Lactate levels in patients taking metformin who exercise 
To date, the tested intensity of exercise in patients with T2DM was moderate in most studies. 
A recent study investigated the role of metformin on glucose kinetics during moderate exercise 
(60% VO2max for 45 minutes).271 The results showed that mean plasma lactate concentrations 
were significantly higher during and after exercise, as well as during recovery, in all patients 
in the T2DM group compared to those of subjects in the healthy control group; whilst patients 
with T2DM receiving metformin had significantly higher mean lactate levels in recovery 
compared to the levels in healthy control group. The authors suggested that the elevated plasma 
lactate concentrations in patients with T2DM was not an unexpected finding in hyperglycaemic 
patients, since an enhanced glycolysis rate in skeletal muscle was observed in their results. The 
lactate recoveries were similar between patients with T2DM treated and un-treated with 
metformin. The authors concluded that metformin as well as exercise could be undertaken in 
combination in patients with T2DM, as the results suggested that the increasing lactate levels 
were more likely related to the exercise rather than metformin.  
Another study272 also found that lactate concentrations were significantly higher in the 
metformin-treated group at recovery compared to the glibenclamide-treated or healthy control 
groups. The intensity of exercise used in this study was also moderate (50% VO2max for 45 
minutes). The authors suggested that the higher lactate in the metformin-treated group may be 
due to the interference with lactate clearance. 
However, the observations from other studies revealed little or no difference in lactate 
levels during exercise in patients with T2DM receiving metformin.273, 274 One of the studies273 
reported that maximal plasma lactate levels or mean plasma lactate levels during exercise did 
not correlate with the metformin plasma concentration. The study also reported that the plasma 
lactate concentration fell more slowly following metformin administration than after placebo, 
or after conclusion of the exercise.  
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A study conducted in Canada275 determined the effect of metformin in response to 
submaximal exercise. The initial exercise intensity used in this study was mild and increased 
gradually, which was a combination of 30% VO2max for 15 minutes, 60% of VO2max for 15 
minutes and 80% VO2max for 5 minutes. Elevated lactate levels were reported in metformin-
treated patients compared to patients receiving placebo.275 High intensity training could be 
dangerous if there were any disease-related limitations of the cardiopulmonary system.229 
 
 Lactate levels in patients taking metformin who are HIV positive and receiving 
NRTI therapy 
Due to a potential mitochondrial toxicity resulting from the interference with oxidative 
phosphorylation from NRTIs, there is a potential risk associated with increased lactate levels 
in HIV-positive patients who were treated with a NRTI. A prospective, randomised, double-
blind, placebo-controlled study compared the effects on body fat after 1 year of therapy with 
either gemfibrozil (1,200 mg per day) or metformin (1,700 mg per day) in HIV-infected 
patients on protease inhibitor-containing highly active antiretroviral therapy.276 The results 
showed no significant changes in plasma lactate levels in all the study groups. Results from 
another two studies for shorter treatment durations (three months in each study) also showed 
that both low dose (1,000 mg per day) or moderate dose (1,700 mg per day) metformin did not 
influence the lactate levels.234, 277 One of these two studies277 demonstrated that a combination 
of metformin and exercise improved cardiovascular and biochemical parameters significantly 
more than in patients receiving metformin alone. But the results in both studies may have to be 
interpreted with caution since the sample sizes were small and strict eligibility criteria 
precluded participation of patients with known contraindications (i.e. liver or kidney disease).  
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 General discussion  
In patients without any contraindications listed in the official product information, metformin 
is the first-line oral therapy for patients with a diagnosis of T2DM. Although an increasing 
number of literature reports showed that metformin was prescribed in patients with 
contraindications to its use, the incidence of LA did not seem to increase.26, 278 In this review, 
the reported lactate levels varied among different studies. Although some studies reported 
significantly increased lactate levels in metformin-treated patients compared to the baseline 
(before initiating metformin) or non-metformin users, the lactate levels mostly remained in the 
normal range.  
In balance the benefits and risk of metformin therapy, conditions including stable 
coronary artery disease, acute coronary syndrome, and stable congestive heart failure should 
not be considered as absolute contraindications to the use of metformin in patients with 
T2DM.133 In addition, CKD, with appropriate dosage reduction of the drug, should not be 
considered an absolute contraindication to the use of metformin. Thus, recent data and reviews 
have suggested no increase in the incidence of LA in the increased metformin users with 
diminished renal function.26, 133, 270 Most recently, the United States Food and Drug 
Administration (FDA) announced that metformin can be used safely in patients with mild and, 
in some with moderate kidney impairment. With the latest recommendation from FDA, a 
patient’s eGFR should be obtained before initiating metformin and the drug is not 
recommended to start in those with an eGFR between 30-45 ml/min per 1.73m2.279 Besides, 
for patients whose eGFR declines to 30-45 ml/min per 1.73m2 during the treatment, the risk 
and benefits should be assess before continuing metformin.   
The debate remains as to whether metformin could be started/ continued in patients 
with an eGFR of 30-45 ml/min per 1.73m2,280, 281 mainly because there is a potential risk of 
developing acute kidney injury (AKI) in patients with CKD;282, 283 In case of unstable renal 
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function, metformin is recommended to be stopped immediately in any acute events which may 
rapidly cause renal function deterioration or trigger the development of LA, including 
dehydration, gastrointestinal disorders and infectious disease.133, 184, 284, 285  
AKI was not the only acute condition associated with increasing risk of LA, the other 
acute illness, which may be related to pre-existing comorbidities in metformin-treated patients, 
would trigger a sudden large rise in lactate level.280, 286 Cautions of using metformin remained 
in certain conditions such as worsening cardiac failure or myocardial infarction, respiratory 
failure, shock, significant blood loss, sepsis, gangrene and pancreatitis.287 These acute 
conditions could potentially increase lactate levels and lead to LA, and metformin should be 
ceased temporarily or withdrawn.287  
Almost all the MALA cases reported in clinical trials or cases series occurred with pre-
existing comorbidities, including acute medical conditions (i.e. sepsis, infection).104, 196 
Regular lactate level monitoring in metformin-treated patients may not be able to predict the 
sudden changes if LA develops acutely. In 2010, the Japanese Ministry of Health, Labour and 
Welfare approved a metformin formulation which allowed a maximum dosage to increase to 
2,250 mg per day.288 One year after the new regulation was authorised, a caution was added in 
the Japanese metformin product information to give a warning regarding the risk of MALA 
following dehydration, and to recommend renal function testing for the patients at risk, 
including the elderly (aged 75 years or older).289 A study reported288 that the number of lactate 
measurements increased after the regulatory action, but the prescription of metformin to elderly 
patients and overall users stayed constant during the study period (from April 2011 to March 
2013). The authors suggested that doctors considered the benefits of metformin treatment 
administrated under conditions of careful lactate monitoring to outweigh the risk of LA. 
However, the study did not report the incidence of LA in metformin users after the regulation 
and caution being advised.   
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It is still not clear if regularly monitoring lactate levels in metformin users could be 
helpful in minimising the incidence of LA. So far, no consistent association has been 
established between lactate level and metformin concentration or its dose. Since the incidence 
of LA in metformin users remains low, a regular lactate level test may become an extra burden 
to patients and waste of health care resources.  
In metformin-treated patients with T2DM, it is not easy to prove how training-induced 
alteration affect the lactate levels. In this review, the results varied in the included studies, 
which were mostly in design of moderate intensity exercise. Brinkman summarised that various 
factors, which have been suggested in different studies, could affect the lactate levels.229 
Physical training could counteract a diminished oxidative capacity (by increasing the aerobic-
oxidative capacity in patients with T2DM by raising skeletal muscle mitochondrial density,290 
capillary supply291 and oxidative gene expression292), which has been considered to be the 
major cause of elevated lactate. Besides, physical training may improve lactate transport and 
clearance.229 The information for metformin users who combined exercise to control their 
diabetes is still limited; besides, patients with other medical complications (i.e. diabetes-related 
complications, hepatic dysfunction) were normally excluded. Future studies on patients with 
other comorbidities, combining medication treatment and different intensities of physical 
training, are warranted. 
Similarly, only few studies have been conducted to test the lactate levels in NRTI-
treated patients who were receiving metformin, and the sample sizes were small. According to 
the summary of available studies, the lactate levels were not being influenced by these two 
mediations. More studies are required to establish the safe use of metformin in patients also 
receiving NRTI therapy, including dosage recommendations.  
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There are some limitations in this review. Limited studies reported regular lactate levels 
in non-acute conditions, and the majority of these studies were limited by small sample size. 
Besides, most of the studies included in this review were in cross sectional or case-control 
study design. The prospective studies were mostly designed with selective populations, with 
an exclusion of patients with contraindications to the use metformin or any comorbidities. 
However, in practice, patients with diabetes have increased risk of cardiovascular 
comorbidities and other complications such as CKD, which are often conditions that may be 
associated with risk of increasing lactate levels. Due to the heterogeneity of the studies, it is 
not feasible to perform a meta-analysis. Therefore, no definite conclusions on the benefits of 
regular lactate monitoring in metformin users can be made.   
 
 Conclusion  
Studies have reported that treatment with metformin could increase lactate levels compared to 
that of non-metformin users. However, most results showed that the lactate level remained in 
the normal range, which made metformin a good choice in the treatment of T2DM. In patients 
with so-called “contraindications” or unstable medical conditions, regular lactate level tests in 
metformin users may have a potential to capture elevated lactate level earlier and withdraw the 
drug treatment; however, this has not yet been proved. Future research on larger populations 
focusing on measurement of lactate levels in continuous metformin users are warranted.   
 
 
 
 
 
 
Part E
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Chapter 7 Discussion and Conclusion  
The current PI of metformin persists with advising extreme caution for its use, especially in 
fears of the risk of LA. The studies outlined in this thesis were conducted using Australian data 
to evaluate the prescribing adherence of metformin to the PI and therapeutic guidelines, explore 
LA cases that occurred in patients treated with this drug, and summarise the changes recorded 
in lactate levels in chronic users. In total, four original research studies and one review were 
conducted to achieve this aim.  
The strict adherence with the PI was often being disregarded. The review of digital 
medical records of patients admitted to RHH (Chapter 2) found that more than 30% of patients 
were receiving metformin inappropriately (i.e. in present of contraindications or excessive 
dosage). Surprisingly, more than 50% of the patients who were receiving metformin 
inappropriately at admission continued the inappropriate use at discharge, even in the small set 
of survivors who had LA. Inappropriate prescribing of metformin was also common in patients 
living in the community and aged care facilities who received either an HMR or RMMR (0). 
Approximately 13% of patients receiving HMR and 17% of RMMR were receiving metformin 
inappropriately. Heart failure was found to be the most common contraindication in both 
studies (Chapter 2 & 0). Emerging evidence suggested metformin may have benefits in 
lowering the incidence of myocardial infarction, improving morbidity and mortality in patients 
with heart failure and cardiac disease, and potential protective effect against ischaemic 
injury.39, 133, 293 It has been suggested that the contraindication in prescribing metformin in 
patients with heart failure are too strict, as increasing evidence supported that the drug could 
be used safely in this population.39, 133, 136, 293, 294 In patients with heart failure or cardiac disease 
(of stable condition), metformin could be used with caution.  
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The patients included in both studies (Chapter 2 & 0) were mostly elderly: (i) the mean 
age of patients receiving metformin who admitted to the RHH was 68 years; (ii) in the study 
of patients receiving HMR or RMMR, the mean ages were 70 and 82 years respectively, and 
older age was a predictor of inappropriate prescribing of metformin according to the logistic 
regression analysis (with female gender and patients receiving RMMR as the independent 
predictors). Recently published studies reviewing medication usage in the elderly outside of 
Australia also reported that metformin was one of the most common inappropriately prescribed 
medications.253, 254, 295 Elderly patients generally have multiple comorbidities, which can easily 
complicated or contraindicated to the use of metformin. It has been suggested that elderly 
patients with diabetes have a higher risk of both microvascular and cardiovascular diseases, 
geriatric conditions (eg. falls, dementia), and hypoglycaemia compared to non-diabetic 
subjects.296 Among the commonly used anti-diabetic medications (i.e. insulin, sulfonylureas), 
metformin is less likely to cause hypoglycaemia, which may be beneficial in elderly. 
The current AMH (2016) suggests using metformin cautiously in elderly with reduced 
dosage and renal function monitoring, although it was previously recommended to avoid the 
usage in very old people (i.e. > 85 years).297  There are concerns of prescribing metformin in 
geriatrics, as the number of comorbidities increases with age. The underlying medical 
conditions may further increase the risk of lactate elevation (i.e. renal function decreases in 
aging population). However, the usage of metformin in elderly patients has increased over the 
years. A population-based cohort of patients aged 80 years or older with diabetes reported that 
the mainstay of antidiabetic therapy had changed from sulfonylureas (94% to 29%) to 
metformin (22% to 86%) from early 1990s to 2010s.295  
Metformin has also been reported to be underutilised in patients with diabetes. Potential 
under dose of metformin was identified in some patients receiving HMR or RMMR through 
the documented HbA1c and renal function (0). It was recently estimated that metformin was 
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not initiated in nearly 50% of patients with T2DM.226 Although the reason for the suboptimal 
prescribing were not defined clearly, it may be associated with the fear of precipitating LA, 
especially in patients with other underlying medical conditions.  
Approximately 75% of the reported LA cases associated with metformin from the TGA 
(Chapter 4) were found to have other underlying condition(s) which might cause acidosis. In 
the study from RHH which investigated the LA cases (Chapter 5), all patients receiving 
metformin had other risk factor(s) associated with LA (either chronic or acute). It was difficult 
to identify the contribution of metformin in these cases as it occurred in the presence of other 
complications i.e. renal impairment).  
It has been summarised that the drug does not accumulate in metformin-treated patients 
with mild to moderate CKD (eGFR 30-60 ml/min per 1.73m2) without increased risk of LA.225 
The metformin dosage recommendation for patients with CKD in the PI are increasingly being 
disregarded.91, 140, 164, 294, 298 The European Medicines Agency has begun a review on all the PI 
of metformin-containing medicines to look at recommendations on how they were used with 
moderate renal impairment in early 2016. This action is in response to a request form the Dutch 
medicines agency (the Medicines Evaluation Board), which suggested that the evidence may 
not justify contraindicating metformin in patients with moderate reduction of kidney 
function.299 Mostly recently, the FDA announced that metformin can be used safely in patients 
with mild and moderate kidney impairment (but not recommending to start metformin in 
patients with an eGFR between 30-45 ml/min per 1.73m2), and the drug is still contraindicated 
in those with an eGFR below 30 ml/min per 1.73m2.279 Metformin should no longer be 
contraindicated in patients with moderate renal impairment, and all the patients with an eGFR 
> 30 ml/min per 1.73m2 or CrCl >30 ml/min should be safe when treated with this drug.  
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It has been reported that metformin was tolerated in patients with eGFR < 30 ml/min 
per 1.73m2.223 Due to the lack of supportive evidence, the usage of metformin in patients with 
severe CKD (eGFR < 30ml/min per 1.73m2) is still not recommended. A recent study 
conducted in Taiwan,283 which included T2DM patients with advanced CKD (SCr > 530 
µmol/L or stage 5 CKD), reported that the all-cause mortality was higher in metformin users 
compared to non-users. The authors suggested that metformin should be withdrawn in patients 
with stage 5 CKD. But the results from this study did not show that metformin was a significant 
risk factor for metabolic acidosis (including LA and other forms of metabolic acidosis). Also, 
the study did not report the causes of mortality; and the patients included (stage 5 CKD) had a 
short duration of diabetes (< 6 years), which may be suggestive of aggressive kidney disease.300  
It is known that the risk of AKI is higher in patients with CKD.301 AKI is one of the 
most common acute conditions co-existing in LA cases in metformin-treated patients. 
However, it is not generally clear whether metformin caused LA due to the drug accumulation 
in AKI, or if, LA was caused by the AKI (accompanied by dehydration, sepsis/infection) in 
metformin-treated patients. As there is limited evidence of the safe use of metformin in patients 
with severe CKD or those with risk of AKI, the drug should only be used in patients with stable 
renal condition, and further investigation in this population is required.  
Although lactate levels had been mostly documented in case reports/ series of MALA, 
the levels are not commonly being measured in general practice. Several pathways have been 
suggested that metformin increases lactate production; however, the exact mechanism has not 
yet been established in patients with T2DM. The estimation of the incidence of MALA using 
the reports from TGA (Chapter 4) was 2.3 per 100,000 patient-years between 1997 and 2011. 
As the results showed in the review of lactate levels in metformin users (Chapter 6), including 
patients with contraindications (listed in the PI) to its use, the lactate levels did increase in 
metformin-treated patients. But the effect was modest; the reported lactate levels mostly 
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remained in the normal range. There was an observation of increasing number of lactate tests 
being performed in metformin-treated patients;288 however, it is also not clear regarding the 
clinical value of chronically monitoring lactate levels in metformin users. So far, most evidence 
indicates that metformin confers little if any risk of LA. The majority of LA cases reported in 
patients who were acutely unwell, or who had decreased tissue perfusion and shock 
(hypotension, sepsis, etc.).224, 287 If the lactate levels dramatically increase in acute conditions 
due to other reasons, then chronic measurement would not be useful in pre-empting this sudden 
medical illness.  
Plasma metformin levels, are also not routinely measured in daily practice. The 
metformin concentration was not measured in the studies containing in this thesis. But the 
levels have been reported in studies elsewhere with the investigation for the reasons of so-
called “MALA” cases. Whether it is useful to monitor metformin plasma concentration is not 
clear. As the results have varied between studies, there was no relationship established between 
metformin plasma concentrations and lactate levels.74, 302 It has been suggested that metformin 
plasma levels were generally measured many hours after admission.303 The patient’s metabolic 
status (i.e., the presence or the absence of lactic acidosis) may have changed during the time 
delay, even when metformin accumulation persisted.303 If the metformin concentration is a 
time-dependent valuable, which could be practically difficult to report, the plasma metformin 
measurement may not have much value in predicting or minimising LA.  
In the latest systematic review and meta-analysis of 179 trials and 25 observational 
studies, the authors concluded that metformin should remain a first-line therapy for the 
treatment of T2DM.25 They evaluated the comparative effectiveness and safety of monotherapy 
among antidiabetic medications, including thiazolidinediones, metformin, sulfonylureas, DPP-
4 inhibitors, sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor 
agonists, as well as selected metformin-based combinations. The review summarised that 
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metformin could be used for long-term treatment with beneficial effects on HbA1c and weight, 
without causing severe adverse effects.  In addition, metformin was not associated with 
increased risk for LA. 
The studies included in this thesis were all of retrospective design. Due to ethical issues 
and the very low incidence of MALA, it was not possible or practical to design a prospective 
study initiating/ continuing metformin treatment in patients with conditions listed as 
“contraindications” in the PI, which has strict restrictions for prescribing metformin in such a 
population. However, to obtain the information of inappropriate usage of metformin and the 
LA cases, the retrospective design enabled evidence as such to be established. The retrospective 
nature of the study could have rendered some of the data incomplete. The diagnosis of LA was 
based on the lab results or the documentation from the databases. Lastly, this thesis did not 
include information on metformin overdose, as the aim was to improve the safe use of the 
medication when taken in therapeutic dosages. Although LA has been reported in metformin 
overdose, it was not commonly found in metformin-treated patients. 
In summary, metformin is generally safe to use in most patients with T2DM. The 
findings in this thesis support the loosening of cautions when using metformin. The 
“contraindications” listed in the official metformin PI are hindering the usage of this drug.136 
The recommendations regarding the usage of metformin in AMH have been modified over the 
last few years, with the level of restriction being lowered. The recommendations in the official 
PI of metformin are inconsistent with clinical guidelines. It is time to update the PI of 
metformin, to provide a clearer guidance for practitioners when prescribing the drug. With 
individualised risk-benefit assessment, unless it causes side effects or there is a high risk of 
LA, metformin therapy should not be excluded in patients with T2DM.  Metformin could be 
used with caution in patients with stable medical conditions, which are including those 
conditions listed as contraindications in the official metformin PI. Very severe renal 
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impairment (CKD stage 5) would be the only absolute contraindication for the use of 
metformin. For patients with CKD, renal function should be assessed regularly. The drug 
should be ceased in patients who develop GI symptoms (including nausea, vomiting) or 
dehydration.287 It would be necessary to identify the reason for GI symptoms or dehydration 
before re-introducing metformin. Unless the contribution of metformin can be ruled out as a 
potential cause of LA, metformin should not be reintroduced in patients who have had LA, 
especially in those with complications. It is important to ensure the safe use of metformin in 
all patients to enjoy the benefits of this old drug.
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